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I. INTRODUCTION 
I.1 Salivary gland structure and function  
Salivary glands are simple exocrine glands of the oral cavity that assist in 
digestion through production of saliva, which is a mixture of electrolyte fluid, mucous, 
glycoproteins, and enzymes.  Although the major function is to lubricate food and begin 
digestion, saliva also functions as a first line of organismal protection from microbes 
since it contains antibacterial compounds and secretory immunoglobulins.  The three 
pairs of major salivary glands (the parotid, submandibular, and sublingual glands) are 
symmetrically oriented in the oral cavity (Figure 1).  Although, the major salivary glands 
account for the vast majority (>95%) of saliva production, between 800 and 1,000 minor 
salivary glands are dispersed throughout the oral cavity.1  
 
 
Figure 1: Anatomical locations of 
salivary glands. 
Figure adapted with permission.2 
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I.2 Malignancies of the salivary glands 
 The World Health Organization recognizes 22 types of salivary cancer, and 
regardless of histological type, standard treatment is currently limited to surgery with or 
without post-operative radiation therapy.3  Molecular defects in several tumor types are 
beginning to emerge, and there are early reports targeting some of these defects such 
as expression of androgen receptor, amplified HER2, or fused TrkC.  Summarized 
below are the most common forms of salivary cancer. 
 The most prevalent cancer of the salivary glands is mucoepidermoid carcinoma 
(MEC), which occurs primarily in the parotid.3  Mucoepidermoid tumors are graded 
based on the cystic component, presence of neural invasion, necrosis, mitotic cells per 
high power field, and anaplasia.4-6  High grade tumors have an increased risk of 
metastasis and lower survival rates than low-grade tumors.4-6  The most frequently, and 
sometimes only, molecular abnormality in MEC is a translocation of chromosomes 
11q21 and 19p13, which results in activation of Notch target genes by fusing the 
mastermind-like 2 (MAML2) gene, a cofactor for NOTCH transcription, with a gene of 
unknown function.7, 8  Ras pathway activation has also been implicated in MEC; 
mutations in H-ras correlate with high grade tumors and are observed in 18% of MECs.9  
Despite efforts to characterize molecular defects in MEC, neither the t(11:19)(q21;p13) 
gene fusion nor H-ras mutations are currently targetable, and treatment remains 
surgical resection followed by radiation for high grade tumors.  
 Acinic cell carcinomas are salivary tumors whose neoplastic cells have features 
of serous acinar cells.  These tumors are thought to arise directly from serous acinar 
cells or from terminal duct cells with subsequent acinar differentiation.3  Women are 
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slightly more likely to develop acinic cell carcinoma than men, but tumor incidence does 
not seem to relate to age or ethnicity.10  While the majority of acinic cell carcinomas 
present as slow-growing, painless lesions, some patients present with pain or partial 
facial paralysis.10-12  Molecularly, the majority (84% in one study) of acinic cell 
carcinomas exhibit loss of heterozygosity (LOH) in chromosomes 1, 4, 5, 6, or 17, but 
the loci affected vary between tumors.13  Prognostically, ~35% of patients recur 
following surgical excision, with ~16% of patients ultimately succumbing to the 
disease.11, 12, 14  For acinic cell carcinoma, tumor stage is a better predictor of outcome 
than histological grading, and regional and distal metastases associate with increasingly 
poor prognosis.3 
 Mammary analogue secretory carcinoma (MASC) was categorized as a subtype 
of acinic cell carcinoma until 2010.15  Unlike acinic cell carcinoma, MASCs lack serous 
acinar differentiation and the microcystic and tubular spaces within the tumors are filled 
with a bubbly secretion reminiscent of breast secretory carcinoma.15  Testing for the 
t(12;15)(p13;q25) translocation characteristic of breast secretory carcinoma revealed 
that >90% of MASC contain this translocation that is absent in acinic cell carcinomas 
with typical histology.15  In MASC, this translocation fuses the ETV6 and NTRK3 genes 
creating a chimeric tyrosine kinase with transformative potential.16, 17  
 Salivary ductal carcinoma (SDC) represents ~9% of salivary malignancies that 
occurs nearly four-fold more frequently in men.18, 19  SDC arises in each of the major 
and minor salivary glands, but is most frequently found in the parotid.18-21  When 
compared to other salivary neoplasms, SDC presents at later stages due to its 
particularly aggressive growth and high rates of metastasis.18  Histologically, SDC is 
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characterized by an infiltrative cribriform pattern, although patterns of pleomorphic 
adenoma may also be present.3  Genetic alterations in SDC include frequent p53 
mutations,22, 23 amplification and overexpression of HER2/neu,22, 24 and inactivation of 
CDKN2A/p16.25  Androgen receptor is expressed in ~90% of SDCs, and these tumors 
can respond to androgen deprivation therapy.26, 27  Despite molecular characterization 
of SDC, prognosis remains poor with ~65% of patients succumbing to disease, usually 
within four years of diagnosis.3   
 Adenoid cystic carcinoma (ACC) is the second most common salivary cancer, 
characterized by a slow-growing mass prone to perineural invasion and metastasis.  
While local disease is frequently controlled by surgical removal and post-operative 
radiation, this tumor is relentless resulting in very high rates of distant metastases.3  
This tumor subtype is the focus of this dissertation and will be discussed in detail below.   
I.3 Adenoid cystic carcinoma (ACC) 
I.3.1 Discovery of ACC 
Cribiform morphology with characteristic tissue invasion and perineural spread of 
ACC was first described in 1853.28  The tumor was originally described as “cylindroma” 
in 1856 and was not differentiated from the similarly-appearing benign cylindroma until 
1930 when the name “adenoid cystic carcinoma” was coined by J. W. Spies.29  The 
malignant nature of ACC wasn’t established until 1942.30 
Today, ACC has a yearly incidence of between 3 and 4.5 cases per million 
population, making it the second most common form of salivary cancer.31  Outside of 
the parotid gland, ACC is the most frequent salivary gland malignancy.32-34   
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I.3.2 Demographic and risk factors 
Relative to many epithelial cancers, adenoid cystic carcinoma presents at a 
younger age, with the majority of cases occurring in the 5th to 6th decades of life.31, 35-37  
However, ACC can occur in all age groups and is more prevalent in women (55% to 
60% of cases).  To date, female gender remains the only known risk factor, as ACC 
incidence has not been associated with behaviors such as use of alcohol, tobacco, or 
illicit drugs.31-34   
I.3.3 Diagnosis 
ACC normally presents as a slow-growing mass in the oral cavity, salivary gland, 
or other sites of the upper aerodigestive tract, but more advanced tumors can cause 
hoarseness, difficulty swallowing, numbness (of the palate, face, or tongue), pain, and 
facial nerve paralysis.  After identification of a mass in the salivary gland, computed 
tomography (CT) scan and/or magnetic resonance imaging (MRI) is used to better 
define the extent of the tumor involvement including bone and nerve invasion.38  
Fine needle aspiration (FNA) of salivary masses is a quick, inexpensive 
procedure that uses a hollow thin needle to sample masses.  Cytologically, ACC is 
characterized by large globules of extracellular matrix, partially surrounded by basaloid 
cells.39  Cytology of salivary cancers can be challenging with a high rate of false 
negative evaluations previously reported.40  At experienced centers, malignant and 
benign tumors can be distinguished with a sensitivity and specificity of 92.8% and 
93.9%, respectively;41 however, given the known uncertainty of cytology, histopathologic 
evaluation of excised tissue is the gold standard for diagnosis. 
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While histological analysis can easily differentiate ACC from the more frequent 
MEC, polymorphous low-grade adenocarcinoma (PLGA) is more difficult to differentiate 
based on morphology.  Prognostically, ACC is much worse than PLGA, making 
differentiation of these tumor types important.42  PLGA is extremely rare in the major 
salivary glands, so this distinction is mostly relevant to tumors of the minor salivary 
glands where small biopsies further complicate diagnostic difficulties.43  Clinically, 
expression of genes characteristic of these tumors is assessed by measuring protein 
levels with immunohistochemistry (IHC).42, 44-61  As summarized by Darling and 
colleagues, few proteins have been identified which can differentiate ACC from PLGA.62  
Although some markers have preferential expression patterns favoring either ACC or 
PLGA, the only marker with a clear diagnostic difference is vimentin, which is expressed 
in PLGA specimens, but not in ACC.62   
I.3.4 Pathology and histology 
Histologically, ACC consists of small non-luminal, basaloid cells with small to 
moderate amounts of cytoplasm and inconspicuous nuclei.  Cells with myoepithelial 
differentiation predominate with the remaining tumor cells exhibiting luminal epithelial 
differentiation.60, 63  The predominance of these cell types is not particularly surprising, 
since ACC originates from the intercalated duct where luminal epithelial and 
myoepithelial cells are prevalent.  
Three distinct growth patterns are associated with ACC.  The classic and most 
common is a cribriform pattern where cells are arranged into nests surrounding cell-free 
pseudocysts.  ACC tumors that infiltrate into separate gland-like structures containing 
individual central lumens are described as tubular.  This growth pattern is rarely seen 
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alone; tumors with tubular growth often demonstrate cribriform patterning as well.64, 65  
Finally, some ACC tumors demonstrate a solid growth pattern where the cells grow in 
tightly-packed sheets without apparent lumen formation.  This pattern is more frequently 
associated with high tumor grade, poor prognosis, and distant metastases.64-66   
One hallmark of ACC is perineural invasion, which is frequently observed in 
early-stage tumors and has long been considered a marker of poor prognosis and 
distant metastasis.35, 67  However, a recent study found no impact of perineural invasion 
on survival or formation of distal metastases.  Rather, this study identified intraneural 
invasion as an independent predictor of poor prognosis.68  Signaling pathways activated 
in ACC and in neural or neural-supporting cells may explain ACC neurotropism; 
however, mechanisms have not been well established.  
I.3.5 Treatment and prognosis 
Although ACC tumors are typically slow-growing, all grades of ACC are 
considered aggressive given high rates of recurrence.  Standard treatment including 
radical resection, and postoperative radiotherapy provides a high rate of short-term local 
control; however, late recurrence at both local and distant sites frequently occur despite 
this aggressive treatment.69-71  One cause of local recurrences is perineural invasion 
and associated skip lesions, which complicate the ability for surgeons and pathologists 
to ensure tumor-free margins.  Nodal disease is not a cause of recurrence, because 
ACC rarely metastasizes to regional cervical nodal basins.72  Unfortunately, distal 
metastases occur in 40% of cases, spreading primarily to the lungs, but also to the liver, 
kidney, bones, and brain.72 
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Although survival at five years post diagnosis is high (70-90%), survival rates 
dramatically decrease to only 35-40% and 10% at 15 and 20 years, respectively.73-75  
Diminished long-term survival is primarily associated with inability to control distant 
disease, and once distant metastases of ACC are identified, 5-year survival rate is 
approximately 20%.76  Doubling time of pulmonary metastases in ACC have been 
estimated to average 393 days, suggesting that metastasis may have already occurred 
by the time the primary tumor presents clinically and that early detection and local 
therapy may not prevent distant disease.77  The clinical course of ACC suggest that new 
therapies targeting widespread systemic metastases will be needed.   
I.4 ACC research & clinical applications 
I.4.1 Molecular profiling 
I.4.1.1 Exome and genome sequencing 
As with many tumor types, deep sequencing technology has been used to 
investigate ACC.  Studies using exome and whole genome sequencing from a 
combined 84 ACC tumors show that the ACC genome is generally stable with a low 
level of somatic mutations per genome (range 1-36).78, 79  Genetic changes identified in 
ACC were highly diverse, with mutations seen in chromatin regulators, genes 
associated with DNA damage, protein kinase A (PKA) signaling, MYB signaling, and 
PI3K signaling.78, 79  Notably, the most recurrent aberrations identified in ACC are MYB-
NFIB gene fusions detected in approximately 50% of ACC specimens.80  These fusions 
result from the recurrent translocation t(6;9)(q22-23;p23-24) causing a pro-oncogenic 
MYB-NFIB fusion protein.81  Transcriptional activation the MYB-NFIB fusion is induced 
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by super-enhancers (regulatory DNA regions enriched with binding sites for 
transcriptional co-activators) brought to the MYB gene through the fusion.82 
Although MYB-NFIB fusions occur in approximately 50% of tumors, MYB is 
highly expressed in up to 70% of ACC, suggesting alternative mechanisms of MYB 
activation in ACC.  In addition, a MYB gene expression signature occurs in almost all 
ACCs, even those without detectable MYB expression.80  Recently, whole genome 
sequencing identified a novel gene fusion between the MYB family member, MYBL1, 
and the terminal exons of NFIB in approximately one-third of ACC tumors that lack 
MYB-NFIB fusion.  Structurally, MYBL1 is similar to MYB with a nearly identical DNA 
binding domain. Both MYB-NFIB and MYBL1-NFIB fusions produce C-terminal 
truncations of MYB or MYBL1; however, both fusions uniformly retain DNA binding and 
transcription activation domains.  These findings strongly suggest that MYBL1 fusions 
serve a similar role as MYB fusions in ACC.83 
I.4.1.2 Expression array 
To identify genes that stimulate ACC tumorigenesis or behavior, microarray gene 
expression analyses was performed on15 ACCs and five normal salivary tissue 
specimens.65  Consistent with myoepithelial differentiation of ACC, components of the 
extracellular matrix and basement membrane are among the most differentially 
expressed genes when comparing ACC and normal salivary gland.  Sox 4, the highest 
scoring gene, is a transcription factor that functions in the heart, brain, reproductive 
system, and B-cell development; however, the function of SOX4 in cancer is relatively 
unknown.  Additional transcription factors including AP-2α and AP-2γ, which regulate 
genes involved in the development of the neural crest and skin are also differentially 
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expressed.  AP-2 targets include c-Kit, whose expression was previously associated 
with ACC.  Other notable differentially expressed genes are genes associated with the 
Notch signaling pathways (ex: Notch3 and JAG1) and the WNT/β-catenin (ex: casein 
kinase 1, ε and Frizzled-7).  Comparison of the top ranking genes in ACC to 175 non-
ACC carcinomas from 10 biologic sites identified increased expression of versican; 
AP2-γ; casein kinase 1ε; and Frizzled-7 in ACC specimens.65 
Adenoid cystic carcinoma also forms outside the salivary glands, including in the 
breast, lungs, skin, nasopharynx, trachea, and prostate.  ACC of the breast is a rare 
form of triple-negative cancer accounting for <1% of breast cancers.  Unlike most other 
breast cancer subtypes, breast ACC is primarily indolent, contains relatively quiescent 
genomes, and is largely resistant to radiation therapy.  Comparison of ACC of different 
sites of origin reveals notably similar histological and genetic characteristics.  Most 
notably, the recurrent MYB-NFIB fusion seen in salivary ACC is shared with ACC of the 
breast.  Salivary and breast ACC tumors both harbor heterogeneous somatic mutations, 
including genes associated with chromatin remodeling or canonical signaling pathways 
such as FGFR2.  There are, however, some key differences between these diseases, 
including breast ACC lacking the Notch pathway mutations seen in salivary ACC.84     
I.4.1.3 MicroRNA profiling 
A comparative study of 30 ACC specimens with four matched normal salivary 
tissues identified 55 microRNAs whose expression is higher (n = 19) or lower (n = 36) in 
ACC.85  Among those whose expression is elevated in ACC, eight (~42%) represent the 
miR-17-92 cluster and its paralogs.  Even within ACC specimens, this microRNA cluster 
is significantly associated with the clinically aggressive solid pattern of tumor growth and 
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reduced patient survival.  There are no differences seen in microRNA expression 
patterns between tumors with and without the MYB-NFIB fusion,85 possibly because 
most ACCs have expression patterns suggesting activation of MYB.80, 83 
An alternative study on microRNA profiles of ACC screened microRNA profiles of 
ACC compared to the most common otolaryngologic malignancy-head and neck 
squamous cell carcinoma (HNSCC).86   Surprisingly, the resulting expression patterns 
differed by only a handful of microRNAs.  Expression level of five microRNAs (miR-214, 
miR-125a-5p, miR-574-3p, miR-199a-3p/199b-3p and miR-199a-5p) being statistically 
higher in ACC, while only one (miR-452) is significantly increased in HNSCC.  Although 
these miRNAs have been implicated in promoting metastatic niches, regulating tumor 
suppressor genes, TGF-β signaling, oncogenesis, stemness, and tumorigenicity in other 
cancers (including hepatocellular carcinoma, gastric cancer, colorectal cancer, and 
glioma), their function in ACC remains elusive.86   
I.4.1.4 Epigenetic profiling 
Epigenetic changes altering gene expression can relieve pressure for mutagenic 
activation of oncogenes or inactivation of tumor suppressors.87  Rather, these chromatin 
changes modulate the ability of transcription factors, polymerases, and enhancer-
binding elements to interact with DNA.  Cytosine methylation of DNA within CpG islands 
(>200 bp regions with >60% G/C content) of gene promoters results in suppressed 
gene expression.  A methylated CpG island amplification and microarray analysis 
identified seven hypomethylated CpG islands in ACC compared to normal salivary 
tissue, specifically located near the FBXO17, PHKG1, LOXL1, DOCK1, and PARVG 
genes.  Hypermethylation in ACC was found in 32 CpG islands mapped primarily to 
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transcription factors (n = 19).  The remaining 13 hypermethylated genes served a 
variety of functions including, but not limited to, stress response, detoxification, protein 
catabolism, and apoptosis.  Deeper analysis of the hypermethylated transcription factor 
EN1 found that its expression correlates with histological grade, tumor location, and 
patient outcomes.87 
I.4.2 Gene expression in primary tumors 
I.4.2.1 MYB-NFIB fusions and signaling 
As previously mentioned, the most frequent gene aberration in ACC is the 
translocation between MYB (6q22-q23) and NFIB (9p23-24) genes.  Reported 
prevalence of this gene fusion in ACC ranges from 28-100%, but among tumors of the 
head and neck, it is exclusively seen in ACC.15, 88, 89  While the location of the fusion in 
both MYB and NFIB varies between tumors, MYB sequences dominate the fusion 
product, with the most common breakpoint fusing exon 14 of MYB to the last coding 
exon of NFIB.  The resulting fusion protein lacks exon 15 of MYB, as well as the 3’-
untranslated region, containing several negative regulatory regions.  Tumors harboring 
MYB-NFIB fusions demonstrate increased MYB expression compared to normal tissue 
controls.90  The high frequency of MYB fusions and known MYB targets involved in 
apoptosis, cell cycle control, cell growth, and cell adhesion, suggest that MYB-NFIB 
fusions are the most prominent oncogenic driver in ACC.  Recent identification of the 
MYBL1-NFIB gene fusions (8q13;9p23) further suggests that downstream signaling 
through these related transcription factors contribute to tumorigenesis in ACC.83  While 
the exact function of MYB in ACC remains unclear, the predominance of activation of 
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this proto-oncogene and its family member suggests that it will be useful as a diagnostic 
marker, prognostic marker, and/or therapeutic target. 
I.4.2.2 c-Kit 
The receptor tyrosine kinase c-Kit (CD117) is a driver of several human 
tumors,91-93 and it is expressed in 80-94% of ACC.94-96  The ligand for c-Kit is stem cell 
factor (SCF), and c-Kit activation induces pathways involved in hematopoiesis, 
spermatogenesis, growth and migration of melanocytes, and maintenance of progenitor 
cells.97, 98  c-Kit expression has previously been used to isolate progenitor cells from the 
submandibular gland, suggesting that c-Kit may be involved in maintaining cancer stem 
cells in ACC. 
Somatic mutations of c-Kit have been described in gastrointestinal stromal 
tumors, mast cell neoplasms, and seminomas;91-93 however, c-Kit mutations are rarely 
seen in ACC, suggesting an alternative method for activation.  In ACC, c-Kit was initially 
correlated with tumor grade, but further analyses negated these conclusions.95, 99-101  
Disappointingly, c-Kit inhibitors have little-to-no effect against ACC in clinical trials.102, 103     
I.4.2.3 Wnt/β-Catenin 
Activation of the WNT/β-catenin pathway is implicated in many human diseases.  
Mutations of this pathway are found in ~35% of ACC, and expression array studies have 
identified aberrant expression of additional components of the pathway, including genes 
associated with malignancies: Wnt inhibitory factor (WIF1), Galectin-3, and cyclin D1.104, 
105  WIF1 functions as a Wnt receptor antagonist, physically preventing receptor-ligand 
interaction57 and has been associated with a subset of salivary gland tumors, wherein a 
14 
 
chromosomal fusion between WIF1 and HMGA2 causes loss of function of the WIF1 
gene.106  Expression of galectin-3, a key regulator of the Wnt/β-catenin pathway, has 
been associated with increased aggressiveness in a variety of malignancies.107, 108  In 
ACC, galectin-3 is linked to increased regional and distal metastases as well as poor 
prognosis.109, 110  Cyclin D1, a critical cell cycle regulator, is the major downstream 
target of β-catenin signaling.  While neither mutated nor amplified in ACC, cyclin D1 is 
overexpressed in ACC specimens, possibly signifying WNT/β-catenin pathway 
activation.109, 111, 112   
Although studies have aimed to elucidate the connection between WIF1 loss 
and/or galectin-3 gain with induction of cyclin D1 expression in ACC, the mechanism 
appears to be more complicated, and understanding this pathway’s role in ACC will 
require additional research.109, 113  
I.4.2.4 FABP7 
Fatty acid binding protein 7 (FABP7) is one of the five most differentially 
expressed genes between ACC and normal salivary gland, and expression of EN1, 
MYB, VCAN, and FABP7 distinguish ACC tumors from normal salivary tissue and 
benign salivary neoplasms.  Amongst differentially expressed genes, FABP7 expression 
alone correlates with poor prognosis.114 
FABP7 functions by binding fatty acids and other lipids and acts as a cytoplasmic 
chaperone for lipid metabolism.  A member of a larger family of hydrophobic proteins, 
FABP7 is normally expressed in the brain, heart, testis, and adipose tissues.115-117  
Nuclear FABP7 is found in glioblastoma and melanoma, where it correlates with 
reduced survival.118-121  In cribriform and tubular ACC histologies, FABP7 localizes 
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predominantly to the nucleus of myoepithelial cells.114  A much lower level of staining 
also occurs in duct-like epithelial cells lining pseudocysts.  In solid ACCs, nuclear 
FABP7 marks all malignant cells, consistent with the idea that nuclear FABP7 may 
identify aggressive tumor subtypes that demonstrate worse prognosis.114 
The functional consequences of FABP7 expression in general, and especially 
nuclear localization of FABP7, have not been particularly well studied.  However, 
FABP7 has been identified as a Notch target gene,122, 123 and Notch signaling has been 
identified in ACC.  Together, these data suggest that Notch may contribute to FABP7 
expression, and raise the possibility that suppressing FABP7 within these tumors may 
have therapeutic benefit. 
I.4.2.5 Other 
Although MYB/NFIB fusion, c-Kit activation, and WNT/β-catenin have received 
the most attention, many other genes and pathways have been studied in ACC.   
Epidermal growth factor receptor (EGFR) and EGFR family members are 
overexpressed in a variety of cancers.  Expression of these genes assists cancer 
development by inhibiting apoptosis while stimulating angiogenesis.  EGFR is 
overexpressed in ACC where its expression correlates with histological grade, but not 
prognosis.124, 125  Although EGFR is expressed strongly in tumor myoepithelial cells with 
much weaker expression in ductal cells, tyrosine kinase inhibitors (TKIs), including 
those targeting EGFR, show little effect in clinical trials of ACC.102, 103 
Vascular endothelial growth factor (VEGF), a signaling protein that induces 
angiogenesis, may play an important role in ACC.  Tumors harboring increased VEGF 
unsurprisingly also demonstrated enhanced microvessel density.126, 127  Although 
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inhibition of EGFR and c-Kit with TKIs failed to demonstrate significant effects, dual 
inhibition of EGFR and VEGF slowed tumor growth and lung metastases in mice.128  
While these data were initially very encouraging, a study published in 2009 revealed  
that six purported ACC cell lines, including the line used in this study, were misidentified 
and not derived from adenoid cystic carcinoma.129 
Although the implications of perineural invasion in ACC are debated, it is a 
common characteristic of many ACC tumors.  In addition to potential anti-apoptotic 
effects, perineural invasion complicates surgical resection by limiting the ability to 
ensure clear margins.130  A potential mechanism underlying perineural invasion in ACC 
relates to shared neurotrophic signaling.  Brain-derived neurotrophic factor (BDNF) and 
nerve growth factor (NGF), both members of the neurotrophin family, are expressed in 
ACC.  TrkA, the receptor for both of these proteins, is expressed in a subset of ACC 
tumors.131, 132  While BDNF and NGF have been suggested to facilitate perineural 
invasion in ACC, more research is required to confirm this association. 
Neuropilin-2 (Nrp2), a protein co-receptor, is overexpressed in greater than 90% 
of ACC specimens.76  Nrp2 expression correlates with microvessel density, clinical 
stage, vascular invasion, and metastasis, consistent with its role seen in other 
cancers.76  Given the use of contaminated cell lines for behavioral studies, the role of 
Nrp2 in ACC is unknown. 
E-cadherin has long been associated with tumor progression and metastasis.  A 
calcium-dependent transmembrane protein, E-cadherin assists with adherens junctions 
which bind cells together in tissues.  In ACC, like other tumors, E-cadherin expression 
inversely correlates with tumor grade, size, infiltration, and metastasis.133  Unfortunately, 
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E-cadherin is unlikely to be a driver of this cancer, as loss of E-cadherin seems to occur 
later in the progression of the tumor.  Regardless, E-cadherin expression does appear 
to be a prognostic marker in ACC. 
I.4.3 Tools for in vitro and in vivo studies 
I.4.3.1 ACC cell lines 
Research to advance molecular understanding of ACC has been hamstrung by 
the relative rarity of the disease and a complicated history resulting from difficulty 
establishing cell lines.  Before 2009, studies examining behavior and therapeutic 
response of ACC extensively utilized six cell lines (ACC2, ACC3, ACCM, ACCS, 
ACCNS, and CAC2).134-138  After being used for ACC research for more than three 
decades, short tandem repeat (STR) analyses in 2009 found that none of the ACC cell 
lines contained human ACC cells.129  These unfortunate findings negate the validity of 
any research using these cell lines.  
In the wake of this setback, many labs have attempted to create ACC cell lines.  
In 2013, a group from China produced a cell line, SACC-83, from an ACC of the minor 
salivary gland.  Through a five-round selection of intravenous injections and lung 
collections, they derived a daughter cell line with increased metastatic potential (SACC-
LM).135, 139  Although these cell lines have not been confirmed to be from the original 
patient or the primary tumor, the group has done STR analysis which confirmed that 
these two cell lines have the same derivation and are distinct from HeLa cells.  
However, deeper comparison with publically available databases of a broad range of 
cell lines has not been performed.140  While SACC-83 and its derivative line may 
represent true ACC cell lines, distribution of them outside of China has been limited. 
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Another cell line (MDA-ACC-01) was developed in 2014,141 and while early 
passages grew well, population doubling times (PDT) increased at higher passage 
numbers making a long-term cell line impossible to establish.  This cell line was 
immortalized with human telomerase reverse transcriptase (hTERT), which stabilized 
the PDT and allowed the culture to grow to 100 passages without senescence.  Of 
concern, G-banding and Spectral Karyotyping (SKY) analyses identified a 
t(6q25;14q13) translocation in the primary tumor and early passages of the primary 
culture, which began to be lost as early as passage 5 and disappeared entirely by 
passage 10.141  Chromosomal changes in cultured cells could be a sign of 
contamination, or indicate that this culture has lost some characteristics of the original 
tumor. 
I.4.3.2 ACC xenografts 
While creation of in vitro ACC models has been very challenging, efforts to create 
in vivo mouse xenograft models of ACC have been more successful with a reported 
74% success rate for establishing subcutaneous xenografts from primary ACCs.142  
Passage into subsequent mice also succeeded for 15 of the 17 xenografts.  
Unsupervised analyses of expression array data revealed that xenografted tumors 
clustered most closely to their parental tumors with the only exception being a primary 
tumor that clustered more closely to a metastatic tumor, which formed later in the same 
patient.  The resulting xenografts from these specimens formed an independent cluster 
closest to the tumors from which they were derived.  Fluorescent in situ hybridization 
(FISH) analysis of the tumors identified 11 of 12 tested samples to have rearrangement 
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of the MYB locus with 10 of these 11 showing presence of a fusion with the NFIB gene 
that is commonly found in ACC (described above).142   
While xenografts provide a powerful tool for ACC research, they are expensive to 
maintain, greatly amplifying the cost of experimentation.  Distribution of xenografts also 
presents challenges since exchange of xenograft-bearing animals between institutions 
can be difficult.  As an alternative, viable xenograft tissue can be shared, but viability 
can be decreased based on shipping time and conditions.  Finally, xenografts do not 
allow the freedom to manipulate gene expression that exists with cell lines, limiting 
experimental options primarily to testing effects of established drugs.   
I.4.4 Studies in vitro and in vivo 
Many studies have been completed using presumed ACC cell lines ACC2, 
ACC3, ACCM, ACCS, ACCNS, and CAC2, both before and after their misidentification 
was reported.  Since findings in these cell lines do not apply to ACC, these results will 
not be discussed.  While SACC-83 and SACC-LM have not been extensively vetted, 
there is no data to disprove their validity at this time. 
I.4.4.1 Genes contributing to migration, invasion, and perineural invasion 
Using SACC-83 cells, depletion of microtubule-associated tumor suppressor 
gene (MTUS1), a tumor suppressor associated with many cancer types, alters ACC 
behavior.143   Lower MTUS1 expression in ACC tumors correlates with increased distant 
metastases and reduced survival,143 and MTUS1 expression is lower in the more 
aggressive, SACC-LM cells compared to the isogenic line SACC-83.  Reintroduction of 
MTUS1 inhibits migration and invasion of SACC-LM cells and correlates with reduced 
20 
 
levels of Slug, vimentin, and activated extracellular-regulated kinase 1/2 (Erk1/2), while 
depletion of MTUS1 in SACC-83 cells has the opposite effects.143  As vimentin 
expression is not characteristic of ACC, how these results translate to patient tumors 
remains to be seen. 
Expression of PRL-3, a phosphatase correlating with poor prognosis in several 
tumor types,144 is found in ACC tumors where it associated with tumor stage 
(p = 0.009), clinical stage, distant metastasis, tumor site, recurrence, and survival.144  
Comparison of the metastatic cell line, SACC-LM, to its parental line, SACC-83, 
revealed up-regulated PRL-3.144  Reminiscent of MTUS1 depletion, overexpression of 
PRL-3 in SACC-83, demonstrated the same migratory and molecular changes.  
Bmi-1 expression is associated with stem cell self-renewal and tumorigenesis in 
various malignancies.145  Bmi-1 expression in ACC correlates with higher tumor stage, 
increased distal metastases, and reduced progression-free and overall survival.  Bmi-1 
inhibition reduced the migratory and invasive potential of SACC-LM cells while 
suppressing expression of cancer stem cell-associated genes.145   
The chemokine CCL5 and its receptor CCR5 are implicated with tumor invasion 
and metastasis.146, 147  In ACC tumors, expression of both genes is enhanced (CCL5: 
35.9%; CCR5: 70.3%),148 and expression of CCR5 is associated with perineural 
invasion.  SACC-83 cells express CCR5, but not CCL5.  Exogenous introduction of 
CCL5 in SACC-83 cells stimulated migration, invasion, and perineural invasion, and 
these effects were reversed by the CCR5 inhibitor, maraviroc.148 
The most well-known and well-studied tumor suppressor, p53, is not mutated in 
ACC, but its inactivation by other mechanisms affects ACC behavior.  Down-regulation 
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of p53 in SACC-83 cells inhibited apoptosis, increased proliferation, and induced 
expression of genes associated with epithelial-mesenchymal transition (EMT).149  These 
molecular changes following depletion of p53 were accompanied by increased 
perinerual invasion of these cells, suggesting that p53 may function in perineural 
invasion of ACC by facilitating EMT.149 
I.4.4.2 mTOR signaling 
mTOR signaling is a characteristic of several human malignancies.150  A 
downstream target of mTOR, phosphorylated-S6 (p-S6, S235/236), is significantly 
increased in ACC compared to pleomorphic adenoma or normal salivary gland.151  
Targeting of mTOR by rapamycin in SACC-83 cells reduces xenograft growth and 
suppresses expression of p-S6, p-Stat3 (T705), PAI, EGFR, and HIF-1α.151 
PTEN loss, as a potential mechanism of mTOR activation, is associated with 
increased phosphorylation of S6 in ACC tumors,152 and the more aggressive SACC-LM 
cells demonstrate reduced PTEN expression compared to parental SACC-83 cells.  
Inhibition of PTEN expression in SACC-83 cells increases proliferation, migration, and 
invasion in vitro, and stimulates tumor growth in vivo.  Conversely, inhibition of 
PI3K/mTOR signaling with NVP-BEZ235 suppresses tumor growth and metastasis, cell 
proliferation, migration, and invasion in both cell lines.152 
Together, these studies indicate that mTOR signaling may contribute to ACC 
proliferation, angiogenesis, and metastasis and may have therapeutic relevance in 
ACC.  
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I.4.5 Clinical trials  
Despite years of research efforts identifying potential drivers and markers of ACC 
and many clinical trials, recommended treatment is limited to surgical resection and 
radiation.  At the time of writing, efficacy of chemotherapy is not proven, and no targeted 
therapies are approved for treatment.153 
I.4.3.1 Chemotherapy 
Chemotherapy is reserved as a palliative measure for patients with metastatic 
and incurable ACC.  A study combining cisplatin with 5-fluorouracil (5-FU) found the 
toxicity of this pairing to be manageable,154 with only three of 11 (~27%) patients having 
any response (all partial responses), but with 64% of patients reporting symptom 
relief.154  The median times to disease progression and survival was nine months and 
12 months, respectively.   
Similar results were shown in ACC patients treated with epirubicin, gemcitabine, 
and mitoxantrone.  Of 20 patients treated with a low-dose regiment of epirubicin for 
eight weeks, two (10%) partial responses were observed, and another 10 (50%) 
demonstrated disease stabilization.155  Despite this modest objective response rate, 
improvement of symptoms was seen in ~30% of patients within the 8-week treatment 
period.155  No responses were seen in ACC patients treated with gemcitabine, but 6 
month stable disease was reported in 48% of treated patients.156  Mitoxantrone 
treatment resulted in a complete response rate in one patient, but no partial 
responses.157  A subsequent phase II study examined effectiveness of mitoxantrone on 
32 chemotherapy-naïve ACC patients revealing a partial response rate of 12%.158  
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Combined, these studies suggest that epirubicin gemcitabine, and mitoxantrone have 
little activity in treating recurrent or metastatic ACC. 
I.4.3.2 Targeted therapy 
The receptor tyrosine kinase c-Kit is expressed in normal salivary tissue and is 
upregulated in ACC compared to other head and neck tumors.  Because of its 
expression in ACC, c-Kit was trialed in patients with recurrent or metastatic ACC.  
Imatinib (Gleevec) was used to treat 14 patients, including 10 patients whose tumors 
expressed c-Kit.  No objective responses were seen.  Rather, all but two tumors 
progressed on therapy.103  Likewise, in a trial of Imatinib in c-Kit-positive ACC 
metastatic to the lungs found that imatinib may have accelerated disease progression 
with three of five patients having disease progression within 2-3 weeks of treatment and 
succumbing to disease within six months.102  Despite dismal results of trials using 
imatinib as a single agent, combination of imatinib and cisplatin was trialed in patients 
with ACC.159  c-Kit overexpression was required for enrollment, and treatment consisted 
of a two month run of imatinib followed by concomitant imatinib and cisplatin for six 
cycles, then a maintenance regiment of single agent imatinib until disease progression.  
A partial response, as measured by decreased fluorodeoxyglucose positron emission 
tomography (FDG-PET) was seen in 11%, while 68% of patients had stable disease.  
However, median progression-free and overall survival times were only 15 months and 
35 months, respectively.159  Taken together, these data suggest that as a single agent 
or in combination, imatinib is not effective in ACC.  
EGFR is expressed in ACC125 prompting a trial of lapatinib, a dual inhibitor of 
EGFR and ErbB2 (HER2) tyrosine kinase activity, that enrolled patients with ACC and 
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other malignant salivary gland tumors.160  Amongst 19 ACC patients enrolled, there 
were no objective responses despite expression of EGFR and/or ErbB2 in 88% of these 
patients.  Although lapatinib was well tolerated it is not useful for treatment of ACC.160  
Likewise, a trial of the EGFR targeting antibody, Cetuximab revealed no responses; 161    
however, 47% (12/23) had stable disease for at least six months.  In these small 
studies, the time to progression with cetuximab treatment was nearly double that 
observed with single agent lapatinib therapy.161  
The less specific tyrosine kinase inhibitor, sunitinib (Sutent), which inhibits 
vascular endothelial growth factor receptor (VRGFR), c-Kit, platelet-derived growth 
factor receptor (PDGFR), ret proto-oncogene (RET), and FMS-like tyrosine kinase 3 
(FLT3), was studied in patients with progressive, recurrent, or metastatic ACC.162  No 
responses were observed, and while 62% had stable disease for at least six months, 
median time to progression and overall survival were 7.2 months and 18.7 months, 
respectively.162  
Bortezomib (Velcade), as an inhibitor of 26S proteasome and NF-κB, also failed 
in a trial of ACC patients inducing no responses, but reporting stable disease in 71% of 
patients.163  Combination of bortezomib and doxorubicin, produced a single partial 
response (10%) and a stable disease rate of 60%.163   
A response in an ACC patient treated in a phase 1 trial of the mTOR inhibitor, 
everolimus, prompted a phase II trial of patients with unresectable ACC.164  
Disappointingly, no responses were observed, but 6 month stable disease was reported 
in 38% of patients.164  
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Many other studies are underway attempting to identify an effective target in 
ACC.  Ongoing clinical trials include dovitinib (FGFR3 inhibitor which may affect other 
RTKs), axitinib (TKI), pazopanib (TKI), vorinostat (HDAC inhibitor), nelfinavir (protease 
inhibitor with anti-retroviral capacity), HPPH (photosensitizer for photodynamic therapy), 
erlotinib (EGFR inhibitor), Trastuzumab (antibody inhibiting HER2/neu), pemetrexed 
(folate antimetabolite), and docetaxel (anti-mitotic chemotherapeutic).  Results of these 
studies are pending. 
The rate of failure for these clinical trials is remarkable and indicates that 
therapies were chosen without adequate preclinical data.  The absence of cell lines or 
short-term cultures to evaluate drug efficacy likely contributed to the universal failure of 
these studies. 
I.5 Cancer stem cells 
I.5.1 Cancer stem cell hypothesis 
The cancer stem cell (CSC) hypothesis professes that a subpopulation of 
tumorigenic cells with stem cell properties, including self-renewal and differentiation, are 
required for tumor maintenance.  Cancer stem cells can regenerate to create all cellular 
subpopulations that may exist in a mixed tumor.  As a mechanism of tumor resistance to 
therapy, CSC remain quiescent, allowing them to evade cell death induced by chemo- 
and radio-therapies.  The first evidence supporting this hypothesis was published in 
1994, when Lapidot et al. identified a population of stem-like cells within myeloid 
leukemia that effectively recapitulated patient tumors as well as demonstrated increased 
tumorigenic potential in non-obese diabetic severe combined immune-deficient 
(NOD/SCID) mice.165  Conversely, the population of non-stem cells from the same 
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tumor were unable to form xenografted tumors.  Cancer stem cells have since been 
identified in a wide variety of tumors (e.g. brain, pancreatic, ovarian, colorectal, head 
and neck, and liver cancers)166-169 that are distinguished by a variety of markers 
including: CD44+/CD24- cells in breast cancer,169 CD44+ in head and neck cancer,170, 
171 and aldehyde dehydrogenase 1 (ALDH1) in breast and gastric cancers.172, 173   
I.5.2 Cancer stem cells in ACC 
 Conflicting evidence regarding the presence of cancer stem cells in ACC has 
been reported.  Isolation of cells with high and low ALDH1 activity from ACC primary 
tumors and xenografts revealed increased spheroid formation in culture, and xenograft 
tumorigenicity and metastatic potential in cells with high ALDH1 activity.174  On the other 
hand, immunohistochemical analysis of ALDH1 expression in primary ACC revealed no 
expression in epithelial cells in 89% of ACCs.175  Further, ALDH1 expression in ACC did 
not correlate with tumor size, perineural invasion, or overall survival.175  Although it is 
hard to reconcile these findings related to ALDH1 as a marker for ACC stem cells, 
tumorigenicity assays are convincing that stem cells likely exist in ACC.176  
I.6 Other tumors with neural crest origin 
Expression profiling of salivary ACC reinforced histological interpretation that 
ACC tumors include cells of a myoepithelial lineage.  During development, progenitors 
of myoepithelial cells migrate from the neural crest into tissues, and in adult life these 
cells differentiate into myoepithelial cells, but maintain expression of neural crest stem 
cell markers such as SOX10.  Other tumors derived from the neural crest lineages 
include melanoma, glioblastoma, and neuroblastoma.  Additionally, the basal-like 
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subtype of breast cancer develops from the basal/myoepithelial cells from a gland that 
is very similar structurally to the salivary gland. 
I.6.1 Melanoma 
Melanoma is a highly aggressive malignancy that arises from pigment-producing 
melanocytes of the skin. Unfortunately, incidence of this disease, which accounts for 
~60% of deaths from skin malignancies, is on the rise.177  Risk factors for melanoma 
include family history, nevi formation, age, fair skin, and exposure to UV radiation.178  
Common drivers of melanoma include B-Raf (mutated in >60%), N-Ras (mutated in 
18%), c-Kit (copy number increase in 36-39% of acral or mucosal melanomas), and 
PI3K/Akt/mTOR pathway members (mutated in 43-60%).177   
The majority of melanomas contain cells with neural crest stem cell (NCSC)-like 
characteristics, including expression of SOX10.  Cancer stem cells from melanomas 
establish xenograft tumors from very few cells, and these tumors support distant 
metastases mimicking behavior of the parent tumor.179-181  Suppression of SOX10 
expression in mice prevented giant congenital naevi and melanoma even when 
melanoma formation was driven by forced expression of mutant N-Ras in melanocytes.  
The critical role of SOX10 in melanoma extends to melanoma cell lines where SOX10 
suppression reduced proliferation, increased apoptosis, and demonstrated aberrant 
differentiation.182  
I.6.2 Neuroblastoma 
In children, the most common extracranial tumor is neuroblastoma.183  The origin 
of these tumors is believed to be NCSCs from which sympathetic neural ganglia and the 
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adrenal medulla are derived.  Although neuroblastoma is a non-glandular solid tumor, 
molecular profiles of this tumor demonstrate similarities to ACC.  This may relate to a 
common neural crest cellular origin.  In addition to SOX10, which is expressed in neural 
crest stem cells, neurotrophin signaling is required for normal neuronal cell lineage 
distinction and is active in both neuroblastoma and ACC.131, 132, 184, 185  In 
neuroblastoma,186 expression of neurotrophin receptors TrkA and TrkC are associated 
with favorable prognosis possibly related to their role as death receptors in the absence 
of ligand.187  Conversely, TrkB expression is involved in increased proliferation, 
stimulated migratory potential, chemoresistance, and is associated with the unfavorable 
MYCN amplification.188  ACCs also express neurotrophin receptors, but the role of 
neurotrophin signaling in ACC remains to be fully explored. 
I.6.3 Glioblastoma 
Glioblastoma (GBM) is the most prevalent tumor of the central nervous system.  
Despite rarely metastasizing to distal organs, GBM is characterized by extensive 
invasion of surrounding brain tissue.  Although targeted therapies are beginning to 
emerge, primary treatment remains maximal surgical resection followed by 
chemoradiotherapy and subsequent chemotherapy.  While this has proven to extend 
survival with generally moderate side effects, cure remains elusive, and patients 
ultimately succumb to the disease.189   
Cancer stem cell populations in glioblastoma have been well characterized and 
studied.  The most common marker of CSCs within GBM is CD133 (Prominin-1), a cell 
surface glycoprotein that is characteristic of neural crest stem cells.190  CD133-positive 
glioblstoma cells have increased self-renewal capabilities, proliferation, xenograft 
29 
 
tumorigenesis, and neurosphere formation.  Compared to control NCSCs, neurospheres 
formed from CD133+ GBM cells proliferate more rapidly and form more secondary 
spheroids.  CD133+ cells injected into mice recreate all aspects of the original tumor by 
forming oligodendrocytes, astrocytes, and neurons. 
I.6.4 Basal-like breast cancer 
Breast cancer remains the most common malignancy in women worldwide, 
causing approximately half a million deaths each year.  Microarray gene expression 
analysis identified several subtypes of breast cancer including: luminal A, luminal B, 
basal-like, and Her2/Neu.191  The luminal subtypes were generally ER+ and/or PR+, 
Her2/neu+ (luminal A, ~40%), or ER+ and/or PR+, Her2/neu- (luminal B, ~20%),  and 
the Her2/neu subtype is distinguished by expression of Her2/neu in the absence of ER 
or PR expression.191-194  
Gene expression in the basal-like subtype (~15-20% of all tumors) suggests that 
the basal epithelial layer which, like in ACC, is made up of myoepithelial cells (Figure 2), 
is the cell of origin.191  Basal-like tumors usually lack expression of ER, PR and 
Her2/neu (triple negative) explaining their resistance to hormone therapies and 
contributing to their notoriety as having the poorest survival of any breast cancer cluster.      
Arising from a similar environment and possibly similar cell of origin as ACC 
(Figure 2), basal-like breast cancer remains one of the most insidious subtypes of 
breast cancer.195  As with ACC, the primary treatment modality for basal-like breast 
cancer is surgery and radiation.  Systemic chemotherapy is also used, but results are 
disappointing.196  Basal-like breast tumors remain a therapeutic challenge, and patients 
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with basal-like tumors have a high risk for early relapse, visceral and brain metastases, 
and eventual death.197 
 
Figure 2: Comparative structures of (A) salivary and (B) mammary glands. 
Images adapted with permission.198, 199 
I.7 Introduction conclusions 
ACC is an insidious malignancy with poor patient prognosis.  Efforts to identify 
new options for therapy have been hampered by the low number of tumors, the paucity 
of funding, and the inability to establish cell cultures to accelerate preclinical studies.  
Clinical trials with chemotherapeutic or targeted agents against molecular markers of 
ACC have had disappointing results.  To date, surgical resection with or without 
radiation remains the standard of care despite frequent failure at preventing recurrent 
disease.  However, recent studies suggesting cancer stem cells in ACC may present a 
new direction for treatment of this disease. 
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II. RESULTS 
II.1 TrkC Signaling is activated in adenoid cystic carcinoma and requires NT-3 to 
stimulate invasive behavior 
Adapted from manuscript published in Oncogene.200 
II.1.1 Abstract 
Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, are 
limited to surgery and radiotherapy.  Based on expression analysis performed on clinical 
specimens of salivary cancers, expression of the neurotrophin-3 receptor TrkC/NTRK3, 
neural crest marker SOX10, and other neurologic genes were identified in ACC.  TrkC 
was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in 
mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma.  
Expression of the TrkC ligand, NT-3, and Tyr-phosphorylation of TrkC detected in this 
study suggested the existence of an autocrine signaling loop in ACC with potential 
therapeutic significance.  NT-3 stimulation of U2OS cells with ectopic TrkC expression 
triggered TrkC phosphorylation and resulted in Ras, Erk1/2 and Akt activation, as well 
as VEGFR1 phosphorylation.  Without NT-3, TrkC remained unphosphorylated, 
stimulated accumulation of phospho-p53, and decreased p-Akt and p-Erk1/2.  NT-3 
promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton 
restructuring in TrkC-expressing U2OS cells.  Immunohistochemical analysis 
demonstrated that TrkC-positive ACC specimens also expressed Bcl2, a Trk target 
regulated by Erk1/2.  In normal salivary gland tissue, both TrkC and Bcl2 were 
expressed in myoepithelial cells, suggesting a principle role for this cell lineage in the 
ACC origin and progression.  Sub-micromolar concentrations of a novel potent Trk 
inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic 
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behaviors in U2OS cells with ectopic expression of TrkC.  Pre-clinical studies on ACC 
mice xenografts revealed growth inhibition and low toxicity of AZD7451. In summary, 
this study identified a previously unrecognized pro-survival autocrine neurotrophin 
signaling pathway in ACC and linked it with cancer progression. 
II.1.2 Introduction 
ACC is one of the most frequent (22%) types of salivary gland cancers,201 and is 
among the most unpredictable and devastating tumors of the head and neck. ACC is 
characterized by insidious local spread and propensity for perineural invasion and distal 
metastases to lungs and bone.202  Most ACCs are treated surgically with or without 
postoperative radiotherapy.  Insufficient molecular insights into signaling that drives 
tumorigenesis and neural tropism in ACC combined with lack of reliable cell lines129 are 
major impediments to the development of better treatment for this insidious cancer.  
With the goal to characterize signaling pathways involved in tumor growth and invasion 
and to enhance therapeutic insight, expression analysis of macro-dissected primary 
ACC specimens was performed.  From this study, TrkC/NTRK3, a receptor tyrosine 
kinase that binds neurotrophin-3 (NT-3), was identified in ACC.  Interest in TrkC was 
further stimulated by its overexpression in other cancer types (e.g., neuroblastoma,203 
melanoma,204 and breast cancer205), trophic stimulation by NT-3, and by the availability 
of small-molecule Trk inhibitors.206  Trk receptors and neurotrophins are involved in 
almost all stages of neural development,207-210 where TrkC conveys NT-3-dependent 
pro-survival effects but triggers apoptosis in the absence of ligand.211  Inactivating 
mutations in TrkC/NTRK3 have been recently associated with Hirschsprung disease, a 
developmental disorder characterized by the absence of ganglion cells in the 
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mysenteric and submucosal plexi likely attributable to defects in neural crest migration, 
differentiation, or survival.212, 213  In cancers, where TrkC activities are not fully 
understood, TrkC pro-survival signaling was found to prevail over apoptotic signaling in 
the presence of NT-3,214, 215 or when ligand requirement is bypassed by activating 
mutations216 or fusions.217  Potentially activating somatic mutations in the TrkC kinase 
domain have been reported in breast, lung, colon, and pancreatic cancers.216, 218-220  
Rearrangements of NTRK3 and ETV6 genes (an ETV6–NTRK3 fusion) have been 
detected in congenital fibrosarcomas, secretory breast carcinomas, and mammary 
analog of secretory carcinoma of salivary glands.15, 17, 221  Overexpression of wild-type 
TrkC and/or other neurotrophin receptors (TrkA, TrkB and p75/NGFR) has been 
detected in cancers, including medulloblastoma, neuroblastoma, and melanoma.  The 
developmental cell of origin for all of these tumors is derived from the neural crest.222 
Recent evidence suggests that TrkC/NT-3 signaling is linked with invasion in 
medulloblastoma,223, 224 melanoma,204 and breast cancer.205, 225  In addition, TrkC 
expression has been correlated with the invasion into venous and nervous tissues in 
pancreatic ductal carcinoma;226 however, the molecular and cellular mechanisms of 
such activity remain unclear.  To explore the cellular and molecular consequences of 
TrkC signaling, TrkC was ectopically expressed in cancer cells lacking expression of 
any neurotrophin receptors or their ligands.  Herein, TrkC signaling was shown to be 
activated in human ACC and a model of TrkC in U2OS cells revealed that activated 
TrkC stimulated cell motility, chemotaxis, invasion and colony formation in soft agar, as 
well as fillopodia formation.  It was further shown that NT-3-induced TrkC 
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phosphorylation and pro-invasive cell behavior was effectively blocked by sub-
micromolar concentrations of AZD7451, a small molecule pan-Trk inhibitor.227 
II.1.3 Materials and methods 
II.1.3.1 Head and neck cancer patients and tumor specimens.  This study included 
three independent cohorts of head and neck cancer patients treated at Vanderbilt 
Ingram Cancer Center (VICC), the University of Virginia (UVA) Hospital, and MD 
Anderson Cancer Center.  Primary salivary cancer and HNSCC specimens were 
obtained from 36 patients: adenoid cystic carcinoma (n=28), mucoepidermoid 
carcinoma (n=6), adenocarcinoma (n=2), HNSCC (n=10).  Patients who were treated 
between 2003 and 2008 provided written consent to have tissue collected for research 
purposes from the Institutional Review Board (IRB#030062, WGY).  The UVA ACC 
specimens used in the study (n=11) were grown as murine xenografts, as previously 
described.228  
II.1.3.2 RNA isolation and expression array analyses.  Total RNA was either isolated 
from snap-frozen clinical macro-dissected specimens, as described before,229 or from 
cell lines using miRNeasy or RNeasy kits (Qiagen, Valencia, CA, USA).  RNA quality 
and quantity were determined using Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA) and Nanodrop ND-1000 (NanoDrop Products, Wilmington, DE, 
USA).  Complementary RNA was prepared from 100 ng of total RNA following the 
Affymetrix 3′IVT Express kit labeling protocol and standardized array processing 
procedures recommended by Affymetrix, including hybridization, fluidics processing, 
and scanning of the Affymetrix HG-U133 Plus 2.0 arrays.  The raw data (Affymetrix CEL 
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files) were normalized using RMA (Robust Multi-array Analysis).  Gene Ontology (GO) 
analyses of differentially expressed genes were performed using 
WebGestalt,230 GSEA,231 and g:Profiler232 portals. 
II.1.3.3 RT-PCR and sequencing.  To produce NTRK3 cDNA for sequencing from 
clinical RNA specimens, the following primers were designed and used: NTRK3F1 (pos. 
357-376 on NM_002530): 5′-GCTGGGAAGCGTCTGGCTGG-3′; NTRK3R1 (pos. 1269-
1250): 5′-GATGCAGTGCTCCAGGCGCA-3′; NTRK3F2 (pos. 1249-1268 on 
NM_002530): 5′-CTGCGCCTGGAGCACTGCAT-3′; NTRK3R2 (pos. 2811-2786): 5′-
GTATGAATTCATGACCACCAGCCACC-3′.  To specifically amplify isoform d, the 
following primers were used: TrkCFdel (pos. 1497-1515): 5′-
GGAGCCCTTTCCAGTTGAC-3′; TrkCRdel (pos. 1523-1501): 5′-
CTCACTTCGTCAACTGGAAAGGG-3′.  To amplify both isoforms for gel-separation, the 
following primers were used: TrkCisoF (pos. 1426-1446 onNM_002530): 5′-
GGCAACTATACCCTCATTGCC-3′ and TrkCisoR (pos. 1559-1540): 5′-
GGAGGTGTGGGACTCACTTC-3′.  To amplify NTRK3 and NTF3 cDNAs for validation 
by RT–PCR and sequencing, NTRK3 primers (5′-CTGCGCCTGGAGCACTGCAT-3′; 5′-
GAGCAGCTCGGCCTCCCTCT-3′, pos. 1249-1268 and 2082-2063 on NM_002530, 
respectively) and NTF3F primers (5′-GGGCCCGCCAAGTCAGCATT-3′; 5′-
TATCCACCGCCAGCCCACG-3′; pos. 309-328 and 803-785 on NM_002527, 
respectively) were used. 
II.1.3.4 Cell lines and transgenic expression.  The human osteosarcoma cell line 
U2OS was transfected with NTRK3 expression construct (Myc-DDK-tagged ORF clone, 
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NM_002530) purchased from OriGene (Rockville, MD, USA) and validated by 
sequencing.  U2OS clones with constitutive expression of TrkC were produced via 
G418 selection. 
II.1.3.5 Antibodies for western analysis, TrkC phosphorylation assay, and 
immunohistochemical staining.  TrkC/NTRK3, TrkB/NTRK2, p75/NGFR, TGFBR3, 
phospho-Akt(Ser473), and phospho-Erk1/2 rabbit monoclonal antibodies were from Cell 
Signaling (Danvers, MA, USA).  Phospho-Tyr antibody was from BD Transduction 
Laboratories (San Jose, CA, USA).  Polyclonal Ephrin B3 antibody was from Novus 
Biologicals (Littleton, CO, USA), and DO1 p53 antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA).  For IHC, Cell Signaling TrkC antibody 
(1:100 dilution), NT-3 antibody from Santa Cruz Biotechnology (N-20, 1:300), and Bcl2 
antibody from Leica Microsystems (PA0117, Buffalo Grove, IL, USA) were used with 
Novocasra Bond Polymer Refine Detection system, as recommended by the 
manufacturer. 
II.1.3.6 Ras activation and protein phosphorylation assays.  To measure Ras 
activity, Ras Activation Assay kit produced by Cytoskeleton (Denver, CO, USA) was 
used.  Protein phosphorylation was detected using the Human Phospho-Kinase and 
Phospho-RTK Antibody Arrays (R&D, Minneapolis, MN, USA). 
II.1.3.7 AZD7451.  AZD7451 is a potent small-molecule inhibitor of Trk kinases with a 
high degree of specificity and selectivity demonstrated as compared with other 
kinases.227  AZD7451 was found to inhibit the in vitro activity of all three Trk isoforms, 
with an IC50=0.2 nM for TrkA in cells and inhibition of phosphorylation of TrkB and TrkC 
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at 3 nM. AZD7451 also exhibited slow-off rate kinetics for Trk kinases, suggesting for 
increased residence time on the target.  In vitro kinase selectivity assays involving 83 
kinases tested, demonstrated that only 15 (18%) showed <100-fold window versus 
TrkA.  Of these, only FGFR1 and CaMKII showed <10-fold window for AZD7451 as 
compared with TrkA. AZD7451 has also shown potent cellular activity against all three 
TrkA, B, and C receptor isoforms in established cell-based systems overexpressing 
wild-type, full-length forms of human TrkA, TrkB or TrkC at concentrations of <5 nM. 
II.1.3.8 Cell motility, migration, invasion and colony formation in soft agar.  
Scratch (wound healing) assay was performed as described,233 following the inhibition 
of proliferation using mitomycin C at 5 μg/ml.  Migration and invasion assays used 
8.0 μm polycarbonate membrane inserts for 24-well plates (BD Biosciences, Franklin 
Lakes, NJ, USA).  Briefly, 2 × 104 of serum-starved cells were loaded into each insert in 
serum-free DMEM media and incubated in a CO2 incubator for 22 h with or without NT-3 
(PeproTech, Rocky Hill, NJ, USA) added at 100 ng/ml to bottom media supplemented 
with serum.  Colony formation was determined with or without NT-3 (100 ng/ml) in 
0.3% agar/complete DMEM.  In all these experiments, Trk inhibitor AZ7451 was used at 
100 nM. 
II.1.3.9 Immunoprecipitation and mass spectrometry.  Proteins that bind TrkC were 
determined following immunoprecipitation with Cell Signaling TrkC antibodies and 
Dynabeads (Carlsbad, CA, USA).  Protein bands were separated using polyacrylamide 
gel electrophoresis (PAGE) and bands isolated after staining with coomassie blue.  
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Protein identification was determined via mass spectrometry by ProtTech (Norristown, 
PA, USA). 
II.1.3.10 Cytoskeleton visualization.  Mouse monoclonal anti-TUBB2B (Abnova, 
Walnut, CA, USA) with anti-mouse Alexa 555 (Invitrogen, Carlsbad, CA, USA) and 
FITC-phalloidin (Sigma, St Louis, MO, USA) were used to stain cells according to 
manufacturer’s instructions.  Nuclei were counterstained with DAPI. 
II.1.3.11 AZD7451 studies on ACC xenografts.  The in vivo efficacy on AZD7451 was 
evaluated in a series of primary ACC tumor xenograft models228 through the South 
Texas Accelerated Research Therapeutics (San Antonio, TX, USA) program.  Animals 
were maintained in accordance with the Institutional Animal Care and Use Committee 
guidelines.  Female athymic nu/nu mice (Harlan Sprague–Dawley) between 4–6 weeks 
of age were housed on irradiated corncob bedding (Teklad bedding) in individually 
ventilated cages (Sealsafe Plus, Tecniplast, Exton, PA, USA) on a 12-h light–dark cycle 
at 70–74 °F (21–23 °C) and 40–60% humidity.  Mice were fed water ad libitum (reverse 
osmosis, 2 ppm Cl2) and an irradiated standard rodent diet (Teklad 2919) consisting of 
18% protein, 5% fat and 4% fiber.  Fragments of human ACC tumor specimens, ACCX6 
and ACCX9 were subcutaneously implanted and grown to produce cohorts 
averaging n=8 per group.  Tumor-bearing mice were randomized into control and 
treatment groups when tumors reached ~0.2 cm3 in size.  AZD7451 treatment was 
given by oral administration at 50 mg/kg, following a daily schedule for 35 days total 
dosing alongside vehicle (0.5 HPMC/0.1% Tween 80) controls.  To assess AZD7451 
toxicity, animals were observed daily and weighed twice weekly using a digital scale; 
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data including individual and mean gram weights (mean We±s.d.), mean percent weight 
change versus Day 0 (%vD0), and mean percent weight change versus prior 
measurement (%vD−x) were recorded for each group and plotted at study completion.  
To assess AZD7451 efficacy, tumor dimensions were measured twice weekly by a 
digital caliper, and data including individual and mean estimated tumor volumes (Mean 
TV±s.e.m.) were recorded for each group; tumor volume was calculated using the 
formula TV=width2 × length × 0.52.  At the end point, percent (%TGI) values were 
calculated and reported for each treatment group (T) versus control (C) using initial (i) 
and final (f) tumor measurements by the formula: %TGI=1−Tf−Ti/Cf−C; single agent or 
combination therapies resulting in a TGI >58% at study completion were considered 
active in the tested model at the evaluated treatment regimen according to NCI 
guidelines.  Statistical differences in tumor volume were determined using a one-tailed t-
test.  BrdU incorporation studies were performed upon intraperitoneal injection with 
1 mg of BrdU (BD Biosciences, San Jose, CA, USA) in 200 mkl PBS 2 h before killing 
the mice.  Tumor cells positively stained with BrdU-antibody (Cell Signaling) were 
counted from 10 high-power fields (× 40) (>300 cells per field) and proliferative index 
determined as BrdU-positive cells divided by total cell count. 
II.1.4 Results 
II.1.4.1 ACC gene expression signature identifies expression of neurologic stem 
cell markers and elements of the Wnt and Notch pathways  
Microarray expression analyses comparing global expression patterns of human 
salivary ACC (n =7) to normal tissue and other cancers of the head and neck revealed 
that the ACC expression profile differed from salivary mucoepidermoid carcinoma 
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(MEC, n = 6), and head and neck squamous cell carcinoma (HNSCC, n = 10).  
Specimens in this study were collected at the time of biopsy or resection at the 
Vanderbilt Ingram Cancer Center (Table 1).  ACC and MEC were more similar, with 
3345 differentially expressed genes (p < 0.01), compared to HNSCC and the salivary 
tumors, with 7127 (ACC, p < 0.01) and 8137 (MEC, p < 0.01) differentially expressed 
genes. 
Unsupervised clustering of all specimens using the 3345 genes that 
discriminated ACC from MEC identified a hierarchical association that specifically 
segregated all but one of the ACC specimens from all other tumor types (Figure 3A).  
Likewise, MEC and HNSCC clustered together in distinct branches from ACC.  
 Cluster analyses revealed that ACC expressed 210 genes at markedly higher 
levels compared to either MEC or HNSCC.  One of the most immediately notable 
characteristics of this gene set was a large number of probes identifying TRKC as 
expressed only in ACC, which prompted reference to these genes as the TrkC-centered 
signature (TCCS).  GO analyses of the TCCS demonstrated significant enrichment in 
genes associated with the Notch and Wnt pathways (Table 2) that have previously been 
associated with neural differentiation and cancer.234-236  Other genes associated with the 
TCCS included: neural crest stem cell markers SOX10,237 MAP2,238 SALL2,239 and 
SLITRK6;240 melanoma markers SHC438 and MUM139; and surface receptors FGFR1 
and EFNB3. 
To further validate the ability of the TCCS to identify ACC specimens, expression 
patterns of murine xenografts derived from primary ACC specimens (n = 11) were 
analyzed.228  When expression data from the xenografted ACCs were combined with 
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data from primary tumors and re-normalized, unsupervised clustering using the 
previously identified differentially expressed genes clustered 10 xenografts with all but 
two of the primary ACC specimens (Figure 3B).  Consistent with clustering of primary 
ACC (Figure 3A), genes highly expressed in ACC centered on TrkC and confirmed that 
this gene cluster was relatively overexpressed in xenografted and primary ACCs.  
TCCS components, such as EFNB3, GPM6B, SOX10, and TCF7L2 were again 
identified as highly expressed in ACC from the combined analysis.  The TGF-β receptor 
TGFBR3 was also found adjacent to the NTRK3 cluster; however, its expression was 
not limited to ACC, but seen also in MEC, and to a lesser extent in HNSCC. 
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ID Gender Age Site Diagnosis Stage 
ACC-1 F 42 Oral cavity/buccal ACC T1N0M0 
ACC-2 F 86 Oral cavity/hard palate ACC T4N0M0 
ACC-3 F 65 Parotid ACC T2N0M0 
ACC-4 F 75 Submandibular ACC T3N0M0 
ACC-5 M 78 Nasal cavity ACC T2N0M0 
ACC-6 F 61 Nasopharynx ACC T3N0M0 
ACC-7 F 75 Nasopharynx ACC T2N0M0 
AD-1 M 57 Nasopharynx AD T4N0M0 
AD-2 M 60 Nasal cavity AD rT4bN0M0 
MEC-1 M 56 Parotid MEC T1N0M0 
MEC-2 M 65 Parotid MEC T4N0M0 
MEC-3 F 55 Oropharynx MEC T1N0M0 
MEC-4A F 63 Oropharynx MEC T1N0M0 
MEC-4B F 63 Oropharynx MEC T1N0M0 
MEC-5 F 75 Oral cavity/tongue MEC T2N0M0 
MEC-6 F 31 Parotid MEC T1N0M0 
HNSCC-1 M 60 Oropharynx HNSCC T2N1M0 
HNSCC-2 M 74 Oropharynx HNSCC T2N2cM0 
HNSCC-3 M 53 Oropharynx HNSCC T4N2cM0 
HNSCC-4 M 44 Oropharynx HNSCC T1N2cM0 
HNSCC-5 M 49 Oropharynx HNSCC T2N2bM0 
HNSCC-6 M 42 Oropharynx HNSCC T1N2aM0 
HNSCC-7 F 44 Oropharynx HNSCC T1N1M0 
HNSCC-8 M 57 Oropharynx HNSCC T2N2cM0 
HNSCC-9 M 53 Oropharynx HNSCC T3N2bM0 
HNSCC-10 F 79 Oropharynx HNSCC T1N1M0 
 
Table 1: Primary tumor specimens of ACC, MEC, AD and HNSCC used in the study.   
Abbreviations: ACC, adenoid cystic carcinoma; MEC, mucoepidermoid carcinoma. 
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Figure 3: TrkC-centered gene signature (TCCS) distinguishes ACC from MEC and HNSCC.   
(A) Expression profiling of clinical specimens derived from 25 primary tumors (left) and close up of clusters 1, 2, and 3 (right). Colored boxes and 
arrows along heatmap indicate overexpression of TrkC/NTRK3 (green boxes), SOX10 (red box), NFIB (yellow box), TCF7L2 (blue box), and 
multiple genes associated with neurogenesis (blue arrows).  FGFR1 (black box) and EFNB3 (orange box) are clustered with NTRK3. Individual 
specimen codes are shown along heatmap bottom.  (B) Validation of TCCS on 11 subcutaneously grown ACC xenografts derived from an 
independent patient cohort.228   When added to the previous clinical set, 11 independently collected and xenografted ACC specimens (ACCX set) 
showed similar gene signature and clustered with 5 out of 7 primary ACC specimens. Core TCCS elements are shown with colored boxes as 
above. All ACCX specimens are labeled with letter X at the bottom of heatmap with XMA designating MADO4-385. 
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Wnt Notch 
Nervous system 
development 
Neurologic stem 
cell markers 
CTBP1 CTBP1 ATXN3 MAP2 
CTBP2 CTBP2 CRIM1 SALL2 
CXXC4 KAT2A EFNB3 SOX10 
FBXW11 NOTCH1 GPM6B SLITRK6 
LRP6  GPSM1  
SMAD4  NDRG2  
TBL1X  NTRK3  
TCF7L1  SEMA6D  
TCF7L2  SMARCC2  
WNT6  SMARCE1  
Table 2: Enrichment of TrkC-centered gene signature with genes involved 
in the Wnt and Notch pathways, neurologic development and with 
neurologic stem cell markers 
II.1.4.2 TrkC as a marker of ACC 
 TrkC was of particular interest as it had is overexpressed in select cancers (e.g., 
neuroblastoma,203 melanoma,204 and breast cancer205) and stimulated by a neural-
associated gene, NT-3, which could play a role in the characteristic perineural 
invasiveness of ACC, and potent small-molecule Trk inhibitors have been developed.  
However, detecting of TrkC might have been evidence of a broader network of 
neurotrophic signaling in ACC.  Indeed, expression array identified expression of 
neurotrophic receptors p75/NGFR and TrkB/NTRK2 in a subset of ACC.  Expression of 
p75/NGFR and TrkB/NTRK2 was not as ubiquitous as TrkC among ACC specimens, 
and TrkA/NTRK1 expression was not identified in ACC.  Thus, TrkC appeared to be the 
major effector of this family in ACC demonstrating 100-430-fold up-regulation in 17 of 
the 18 studied primary ACC specimens and xenografts compared to normal salivary 
tissue (Figure 4A).  To confirm the expression array data, TrkC protein expression was 
measured by immunoblot in clinical ACC, MEC, and normal salivary specimens, 
revealing markedly increased levels of TrkC in all primary ACC specimens and 
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xenografts studied, whereas expression was at the limit of detection in the remaining 
tissues (Figure 4B).  Expression of other neurotrophic (p75/NGFR and TrkB/NTRKB) 
and membrane (Efnb3 and Tgfbr3) receptors was consistent with microarray results 
(Figure 4B).  Examination of ACC xenografts confirmed high expression of TrkC was 
maintained in this model system (Figure 4C).
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Figure 4: TrkC is expressed in ACC.   
(A) Expression of neurotrophic receptors in clinical and subcutaneously grown ACC xenograft specimens. Expression values of TrkB/NTRK2, 
TrkC/NTRK3, and p75/NGFR were derived from combined microarray study and shown in arbitrary units. Expression of TrkA was not detected. 
(B) Immunoblot validation of TrkC, TrkB, NGFR, and other receptor expression in clinical ACC and MEC specimens compared to normal salivary 
gland tissue (NSG).  In agreement with microarray data, ACC specimens also expressed EfnB3 and Tgfbr3.  (C) Expression of total TrkC protein 
in subcutaneously grown ACC xenografts as compared with clinical specimen ACC-3. Numbers of passages for ACCX2 (either 3 or 8) are 
indicated. Loading control was assessed by Ponceau staining. 
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II.1.4.3 ACC tumors express full-length TrkC and its ligand NT-3 
As activating mutations and fusions of TrkC have been described in diverse 
tumor types, it was important to determine whether ACC specimens contained such 
mutations.  TrkC transcripts were amplified from primary ACC tumors and sequenced, 
revealing that the open reading frames (ORFs) of TrkC from all six TrkC-positive ACC 
tumors were full-length and wild-type.  Remarkably, all of these specimens (ACC1-6) 
expressed the canonical isoform b that encodes a fully active protein (NM_002530), but 
also contained splicoform d (NM_001243101) that lacks exon 10, producing an 8-
amino-acid (aa) in-frame deletion in the juxtamembrane TrkC domain.  This isoform, 
which was expressed in ACC at levels similar to isoform b (data not shown), was 
previously described as a polymorphism,241 but its biological significance remains 
unclear.  
Although TrkC was expressed in the majority of ACC specimens, biological 
effects of TrkC activity in these tumors were unknown.  In other tumor types such as 
neuroblastoma, TrkC expression is a positive prognosticator, likely related to the 
function of TrkC function as death receptor when its ligand is not present.  In order to 
determine if TrkC was active, as a surrogate for ligand presence, phosphorylation of the 
receptor was analyzed.  TrkC immunoprecipitation from lysates of ACC xenografts 
followed by immunoblotting for phosphotyrosine indicated that TrkC is activated in ACC 
(Figure 5A).  To determine if an autocrine loop between NT-3 and TrkC was possible in 
ACC, NT-3 expression was determined in primary (n = 7) and xenografted ACC 
specimens (n = 11).  NT-3 expression was detected and verified by sequencing in both 
primary and xenografted ACC specimens, suggesting that an autocrine survival 
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pathway may be active in ACC (Figure 5B&C).  Levels of NT-3 transcripts showed 
substantial variation from specimen to specimen with no obvious correlation with 
expression of TrkC (R = 0.43).  Taken together, these results demonstrate that ACC 
tumors contain high levels of TrkC, and that TrkC signaling is persistently active in these 
tumors, likely owing to autocrine NT-3 production. 
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Figure 5: Activation of TrkC in ACC.   
(A) Tyrosine phosphorylation of TrkC in ACC xenografts assessed via TrkC-immunoprecipitation.  Rabbit 
IgG was used as a negative control and 1/20th of the protein amount used in immunoprecipitation was 
loaded for Western analysis.  Semi-quantitative detection of NTF3 expression by end-point RT–PCR (B) 
and comparison between NTF3 and NTRK3 levels in clinical specimens of ACC (C). Equal amounts 
(50 ng) of total RNA isolated from clinical (ACC) and subcutaneous xenograft (ACC Xenograft), MEC 
and AD specimens, and normal salivary tissue (NSG) were subjected to 30 cycles of RT–PCR with 
primers for human NTF3, NTRK3, and PPIA (last used as a loading control). Graph shows PPIA-
normalized expression values in arbitrary units. 
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II.1.4.4 Creation and validation of a TrkC-expressing surrogate cell line  
Although a link between TrkC/NT-3 expression and aggressive cancer behavior 
has been established in some tumor types,205, 242 the molecular and cellular 
consequences of TrkC overexpression are not fully understood.  TrkC expression in 
primary and xenografted tumor specimens did not correlate with other neurotrophin 
receptors such as TrkA, TrkB or p75/NGFR (Figures 4A&B), suggesting a special role 
for TrkC in this tumor type.  In order to explore the consequences of TrkC expression 
and signaling, we wanted to disrupt TrkC signaling in vitro; however, due to a lack of 
reliable cell lines in ACC,129 a surrogate cell line with forced expression of TrkC was 
utilized.  For this purpose, human osteosarcoma cells (U2OS) were chosen as they lack 
endogenous expression of neurotrophic receptors or their ligands.  While this model 
may not perfectly replicate the activities of TrkC in ACC, this cell line enabled 
identification of potential molecular mediators and behavioral consequences of TrkC 
signaling.   
TrkC-expressing U2OS cells tolerated high levels of TrkC expression, enabling 
the study of TrkC signaling in the presence or absence of NT-3.  In the absence of NT-
3, TrkC remained unphosphorylated, but stimulation with its ligand induced rapid and 
marked TrkC phosphorylation at tyrosine residues (Figure 6A).  The pan-Trk inhibitor, 
AZD7451 (AstraZeneca) completely prevented/reverted TrkC phosphorylation when 
added at nanomolar concentrations regardless of the presence of NT-3 ligand (Figure 
6A).  As ligand-activated Trk signaling is associated with receptor clustering and 
internalization,243 cellular localization of TrkC with and without NT-3 was assessed by 
immunofluorescence.  Cellular localization was consistent with TrkC receptor 
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clustering/internalization following NT-3 stimulation, as diffuse membrane staining 
changed to a pattern of distinct bright puncta (Figure 6B).  
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Figure 6: TrkC activation in U2OS surrogate cell line.   
(A) NT-3-dependent TrkC tyrosine phosphorylation assessed in TrkC-expressing U2OS cells. (B) Immunofluorescence 
staining of TrkC in TrkC-expressing cells with (bottom row) and without (upper row) NT-3. 
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II.1.4.5 TrkC activation induces proliferative and anti-apoptotic pathways 
In the presence of its ligand, TrkC signaling in non-tumorigenic neural tissue 
promotes survival and proliferation, at least partially, through activation of Ras and Akt 
as its downstream mediators (http://www.genome.jp/kegg/pathway/hsa/hsa04722.html).  
To identify additional signaling pathways activated by TrkC expression in the presence 
or absence of the NT-3 ligand, stably transfected U2OS cells (vector control and TrkC) 
with and without addition of NT-3 were analyzed using phospho-protein antibody arrays 
(Figure 7A).  The most notable difference following TrkC expression was the activation 
of p53 indicated by increased phosphorylation at multiple sites, including the critical S15 
residue (Figure 7A).  Additionally, TrkC expression had a moderate suppressive effect 
on Akt phosphorylation and induced phosphorylation of β-catenin.  Stimulation of TrkC-
expressing cells with NT-3 resulted in a very different profile of pathway activation 
compared with cells expressing TrkC in the absence of ligand.  Upon NT-3 stimulation, 
Erk and Akt were markedly activated in cells expressing TrkC, whereas phosphorylation 
of β-catenin was reduced (Figure 7A).  Phosphorylation of p53 was decreased upon NT-
3 treatment in cells expressing TrkC (Figure 7A), consistent with TrkC acting as a death 
receptor in the absence of its ligand.  Despite TrkC being the only described receptor for 
NT-3, p53 phosphorylation increased in cells lacking TrkC (Figure 7A) when exposed to 
NT-3.  Immunoblot experiments confirmed the effects of TrkC and NT-3 on the 
expression of phosphorylated Akt, Erk1/2, and p53 seen in the arrays (Figure 7B).  
Interestingly, co-immunoprecipitation experiments indicated that TrkC exists in complex 
with p53, and that this association is not dependent upon the presence of NT-3 (Figure 
7C). 
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A similar phospho-receptor tyrosine kinase (RTK) antibody array was employed 
to assess changes in tyrosine phosphorylation following TrkC expression or NT-3 
stimulation.  As expected, TrkA and TrkB phosphorylation were not detected in these 
cells, and TrkC tyrosine phosphorylation was confirmed upon NT-3 stimulation only in 
cells expressing TrkC (Figure 7A).  In addition to stimulating TrkC phosphorylation, TrkC 
expression in the presence of NT-3 triggered VEGFR1 tyrosine phosphorylation, 
suggesting that NT-3 may promote angiogenesis in a TrkC-dependent manner.  
Although TrkC expression has been associated with Ras activation,205, 225 this 
was not assessed by the antibody arrays.  Activation of Erk and Akt downstream of 
TrkC could indicate Ras pathway activation, and to further explore this possibility 
control- (vector) and TrkC-expressing U20S cells were stimulated with NT-3 for 
increasing time periods before measuring activated Ras by determining the amount that 
bound to a peptide of the Ras binding domain (amino acids 51-149) of human Raf1.  
NT-3 stimulation resulted in rapid and sustained Ras activation only in TrkC-expressing 
cells (Figure 7D).  These effects were consistent with previous reports demonstrating 
that Ras is a mediator of TrkC signaling,205, 225 and further suggested that proliferative 
and survival pathways are activated in the absence of additional neurotrophin 
components such as TrkA, TrkB, NGFR, or their ligands. 
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Figure 7: NT-3 induces pro-survival signaling in TrkC-expressing U2OS cells.  
(A) TrkC- and NT-3-dependent phosphorylation of Erk1/2, Akt, β-catenin, and VEGFR1. Tyrosine phosphorylation of TrkC induced by NT-3 is 
shown.  PC, positive controls provided with membranes.  (B-C) Validation of TrkC and NT-3 effects on Akt, Erk1/2 (B), and association with p53 
(C).  (D) Rapid and sustained NT-3-induced Ras activation in cells expressing TrkC.  Loading control assessed by Ponceau staining. 
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II.1.4.6 Phenotypic effects of TrkC activation and signaling 
Ras activation is associated with cellular motility, migration, invasion, proliferation 
and survival.244  To determine the role of TrkC in cellular migration, a scratch assay was 
performed on U2OS cells with and without TrkC expression in the presence or absence 
of NT-3 or the pan-Trk inhibitor AZD7451.  Control cells had no change in migration 
following addition of NT-3, but the gap closure was greatly stimulated by NT-3 in cells 
expressing TrkC (Figure 8A, ~1.8 fold, p<10-5).  Addition of AZD7451 did not 
significantly alter migration of control U2OS cells (P = 0.17) but inhibited the migration of 
TrkC-expressing cells (Figure 8A, ~2.3-fold, p < 3.9 x 10-8).  
To further confirm the results of scratch analyses which suggested that activated 
TrkC stimulated migration, a Boyden transmembrane migration assay was performed 
with and without NT-3 addition.  Consistent with the scratch assay, NT-3 stimulated 
migration of TrkC-expressing U2OS cells (Figure 8B).  NT-3 induced migration of TrkC-
expressing cells was inhibited by addition of AZD7451 (Figure 8B).  Neither NT-3 or 
AZD7451 altered migration of control cells.  A modified Boyden chamber assay using 
matrigel coating as a basement membrane surrogate was used to determine if TrkC 
altered cellular invasion.  Similar to results of the migration assays, the addition of NT-3 
promoted invasion of TrkC-expressing cells (~2.5-fold), but not control cells (Figure 8C).  
Once again, the Trk inhibitor, AZD7451, blocked the increased invasion observed in the 
presence of NT-3.   
To further explore the tumorigenic potential of TrkC-expressing U2OS cells, 
anchorage-independent growth in soft agar was measured.  Although U2OS cells are 
transformed, they inefficiently grow in soft agar, forming very few and relatively small 
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colonies.  Addition of NT-3 to TrkC-negative cells or expression of TrkC in the absence 
of NT-3 did not enhance the ability of U2OS cells to grow in this assay.  Remarkably, 
stimulation of TrkC-expressing cells with NT-3 dramatically increased both number 
(~10-fold, p < 10-9) and size/calculated volume (~9-fold) of colonies that formed in soft 
agar (Figure 8D&E).  Treatment of cells with AZD7451 prevented the stimulatory effect 
of NT-3 on colony formation seen in TrkC-expressing cells.  Together, these data 
suggest that TrkC activation by NT-3 in the absence of additional neurotrophin 
stimulation or co-operation with other Trk receptors increases tumorigenic behavior and 
may drive tumor growth, migration, and invasion.   
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Figure 8: NT-3 promotes motility and chemotaxic migration/invasion in TrkC-expressing cells.  
(A) NT-3 promotes TrkC-dependent motility of U2OS cells in scratch assays with mitomycin C. Scratch 
closure is shown in arbitrary units. Asterisks indicate statistically significant differences.  NT-3 stimulates 
(B) migration through Boyden chamber membranes and (C) invasion through matrigel-covered 
membranes in TrkC expressing cells.  (D-E) NT-3 promotes colony formation and growth in soft agar in 
TrkC expressing cells.  (D) Examples of colony size in the presence or absence of ligand-stimulated 
TrkC.  (E) Average soft agar colony count per visual field in the presence or absence of TrkC, NT-3 or 
the Trk inhibitor, AZD7451.  
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II.1.4.7 Effects of TrkC and NT-3 on cytoskeleton components 
Migration and invasion require coordinated restructuring of the cytoskeleton, and 
Ras activation is involved in this process.245  To examine the extent of cytoskeletal 
rearrangement resulting from TrkC activation, F-actin was stained with phalloidin-FITC 
in U2OS cells.  Following NT-3 stimulation, TrkC-expressing cells had actin patterns 
indicative of cytoskeleton rearrangement including F-actin condensation (puncta) and F-
actin enriched protrusions (Figure 9A).  These effects were similar to the NT-3-triggered 
changes in the morphology of neuroblastoma cells described previously.246  
TUBB2B is a class II b-tubulin described as being exclusively expressed in 
neural tissue (http://biogps.org/) and critically involved in neuronal migration.247  
Expression array analyses revealed that this gene is expressed in the majority of ACC 
specimens (Figure 9B), and overexpression of TrkC in U2OS cells resulted in increased 
TUBB2B expression as assessed by immunofluorescence (Figure 9B).  These 
preliminary studies suggested that TrkC may affect restructuring of the cytoskeleton.  
Taken together, these observations suggested an important role for the TrkC/NT-3 
interaction in cytoskeleton regulation resulting in tumor migration and invasion. 
 
60 
 
 
Figure 9: Association of TrkC with cytoskeletal regulation.   
(A) NT-3 stimulates development of F-actin puncta (yellow arrow, 400x) and F-actin-rich fillopodia (red arrows, middle, 100x; right, 400x). (B) TrkC 
stimulates expression of class II β-tubulin TUBB2B. 
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II.1.4.8 Up-regulation of p-Erk1/2 and Bcl2 in TrkC-positive ACC cells 
Given that there were no ACC cultures for behavioral or biological study, ACC 
tissues were analyzed to determine if they expressed proteins observed in the U2OS 
model system or that had been previously reported.  In agreement with activation of 
Erk1/2 in TrkC-expressing U2OS cells (Figure 7A&B), TrkC has been associated with 
Erk1/2 and Bcl2 up-regulation in cylindromas,248 and up-regulation of Erk1/2 by 
neurotrophins has been linked with Bcl2 up-regulation (http://www.genome.jp/kegg-
bin/show_pathway? hsa04722).  In order to assess whether these finding are also seen 
in ACC, clinical ACC specimens were immunostained to determine expression of 
Erk1/2, Bcl2 and TrkC.  As seen in cylindroma, ACC specimens expressed TrkC, p-
Erk1/2 and Bcl2 in their neoplastic myoepithelial layer (Figure 10).  The patterns of 
expression of Erk and TrkC in ACC tumors varied amongst cells of the basal layer, 
while Bcl-2 was expressed more uniformly; however, expression of these genes 
overlapped at least partially.  Expression of these genes was not detected in MEC in 
agreement with lack of TrkC expression in this cancer.  Interestingly, normal salivary 
gland tissue displayed TrkC and Bcl2-positive signals in myoepithelial cells (data not 
shown).  This finding, however, was not entirely unexpected given the important roles 
that myoepithelial cells have in ACC development.249 
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Figure 10: Expression of TrkC, Bcl2, and phospho-Erk in ACC.   
High levels of TrkC. Bcl2 and Erk1/2 activation in ACC. 
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II.1.4.9 Inhibition of TrkC signaling suppresses ACC tumor growth in vivo 
The effect of TrkC inhibition on ACC xenograft growth was determined using two 
xenograft models of human ACC (1) ACCX6, a xenograft created from a metastatic 
tumor, and (2) ACCX9, a xenograft from a primary tumor.228  AZD7451 was 
administered orally at 50 mg/kg once daily.  In ACCX6, AZD7451 demonstrated a 
marked anti-tumor effect as a single agent (Figure 11A, tumor growth inhibition (TGI) = 
64%, p < 0.05).  However, ACCX9 did not see a significant effect at the 35-day 
experimental course (Figure 11B, TGI = 43%, p > 0.05).  Nevertheless, analysis of 
BrdU-incorporation performed on tumors generated from ACCX9 showed a robust 
reduction in the proliferation index (Figure 11C, PI = % BrdU-positive cells) from 17% to 
5% (p < 10-5), suggesting that AZD7451 inhibited cellular proliferation in ACCX9.  This 
observed difference between anti-tumor effects of AZD7451 in ACCX6 and ACCX9 
could, in part, be due to ACCX9 displaying a sluggish growth profile from days 1-21, 
thus leaving insufficient time in this experiment for drug effects to become significant.  
The observed changes in tumor growth are not likely due to toxicity, as AZD7451 
administration was not accompanied by weight loss of the animals.  These preclinical 
data support further investigation of single agent Trk kinase inhibitors as a potential 
therapeutic option in ACC.
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Figure 11: Assessment of AZD7451 efficacy in vivo.   
(A-B) ACC tumor growth in the ACCX models with or without Trk inhibitor. From day 3 for ACCX6 p<0.05. (C) Reduction in the 
proliferative index (PI) in the ACCX9 model as assessed by BrdU staining. 
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II.1.5 Discussion 
In this study, a novel ACC marker, receptor tyrosine kinase TrkC/NTRK3 was 
characterized as a potential therapeutic target.  Unusually high TrkC expression levels 
were found in ACC (up to ~100-fold as compared with the normal salivary tissue), 
raising an important question if this RTK may serve as a driver of ACC.  Lack of 
activating mutations suggested that malignant ACC cells may benefit from increased 
activity of wild-type TrkC signaling, possibly achieved either via spontaneous TrkC 
dimerization and activation due to overexpression250 or through interaction with its only 
known ligand NT-3.  Given that other neurotrophin receptors did not correlate with TrkC 
expression, TrkC signaling alone was explored for its ability to stimulate pro-invasive 
signaling and cell behavior.  TrkC-expressing U2OS cells in response to NT-3 
stimulated: (1) TrkC tyrosine phosphorylation, (2) Ras, Erk1/2, Akt, and VEGFR1 
activation, (3) cell motility and invasion, (4) chemotaxis toward NT-3, (5) adherence-
independent growth, and (6) outgrowth of F-actin-rich processes typical for migrating 
cells (Figures 7-9).  Without NT-3, TrkC remained unphosphorylated, did not stimulate 
pro-tumorigenic qualities, and had anti-tumorigenic signaling effects including increased 
phosphorylation of p53, in agreement with the dependence receptor paradigm.251  In 
agreement with previous studies, NT-3 was the only neurotrophin capable of activating 
TrkC, as NGF, BDNF and NT-4 failed to induce TrkC phosphorylation (data not shown).  
These observations suggest that highly overexpressed TrkC is oncogenic when NT-3 is 
available, stimulating further research into the autocrine TrkC/NT-3 signaling that was 
discovered in ACC. 
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Without NT-3, TrkC induces apoptosis and thus may suppress tumor 
progression.214  These studies revealed a potential novel molecular mechanism of this 
NT-3-independent mode of TrkC function.  In the absence of ligand, TrkC stimulated 
TUBB2 expression (Figure 9) while inhibiting Akt and Erk1/2 activation (Figure 7A&B).  
TrkC in the absence of ligand stimulated the expression of total and serine-
phosphorylated p53, and this effect was alleviated by NT-3.  Interestingly, 
immunoprecipitation suggested that TrkC is in a complex with p53 (Figure 7C).  Of note, 
TrkA, which is also considered a dependence receptor with a pro-apoptotic function 
similar to TrkC in the absence of ligand,211, 251 binds p53, which mediates TrkA 
activities.252-255  Tumor-suppressive TrkC activities suggest that association of TrkC 
overexpression with good prognosis observed in medulloblastoma4 may be explained 
by lack of NT-3 stimulation.  Indeed, autocrine TrkC/NT-3 loops detected recently in 
neuroblastomas were linked with poor prognosis.215  
Up-regulation of Bcl2 along with TrkC in ACC, which is also observed in CYLD-
deficient cylindromas that overexpress TrkC,248 is an intriguing discovery, given the 
important role that Bcl2 has in cell survival and, particularly, the resistance to radio- and 
chemotherapies.256  High Bcl2 levels detected in ACC tumors (Figure 10) are consistent 
with results reported on four ACC specimens257 and may contribute to the relative 
resistance of this cancer to cytotoxic therapies. 
Expression of TrkC in normal myoepithelial cells of the salivary gland provides an 
interesting insight into the potential cell origin of ACC.  ACC is thought to arise from the 
intercalated salivary duct where myoepithelial cells are abundant,258, 259 and is 
histologically and clinically distinct from MEC, whose origin is linked with the excretory 
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duct.259, 260  Accordingly, expression array data reliably discriminated between these two 
cancers and identified TrkC as one of the most distinguishing markers of ACC.  As 
myoepithelial cells have important roles in normal salivary gland functions and the 
pathogenesis of adenoid cystic carcinoma,261, 262 characterization of TrkC as a 
previously unknown marker of these cells sheds more light onto their function, origin, 
and role in ACC. 
Overall, these findings reveal a previously unknown autocrine NT-3/TrkC 
signaling pathway in ACC that can be targeted with small-molecule inhibitors.  A novel 
pan-Trk inhibitor AZD7451 was characterized in this study as a potent TrkC inhibitor, 
which blocks its tyrosine phosphorylation in a nanomolar range and suppresses 
TrkC/NT-3-mediated cell migration, motility, invasion, and growth in soft agar (Figure 8).  
It is reasonable, therefore, to suggest that this drug may be used to block ACC 
neuroinvasion and growth, and pre-clinical assessment of its activity on murine 
xenografts that models invasive ACC supports its tumor-suppressive properties 
(ACCX6, Figure 11).  In conclusion, distorted neurologic signaling detected in ACC 
advances understanding of its molecular etiology, suggests similarity of its molecular 
pathology with neural crest cancers, and stimulates development of multi-drug 
treatment modalities that target TrkC/NT-3, Ras, Erk 1/2, Akt and Bcl2. 
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II.2 Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast 
basal-like carcinomas 
Adapted from manuscript published in British Journal of Cancer.263 
II.2.1 Abstract 
Salivary adenoid cystic carcinoma (ACC) is an insidious slow-growing cancer 
with the propensity to recur and metastasize to distant sites.  Basal-like breast 
carcinoma (BBC) is a molecular subtype that constitutes 15–20% of breast cancers, 
shares histological similarities and basal cell markers with ACC, lacks expression of ER 
(estrogen receptor), PR (progesterone receptor), and HER2 (human epidermal growth 
factor receptor 2), and, similar to ACC, metastasizes predominantly to the lung and 
brain.  Both cancers lack targeted therapies and have incomplete understanding of their 
molecular drivers contributing to the absence of targetable defects.  Gene expression 
profiling, immunohistochemical staining, western blot, RT-PCR, and in silico analysis of 
cancer expression data sets were used to identify novel markers and potential 
therapeutic targets for ACC and BBC.  For detection and comparison of gene 
signatures, co-expression analysis was performed using a recently developed web-
based multi-experiment matrix tool for visualization and rank aggregation.  
Characteristic and overlapping SOX10 gene signatures that contained a large set of 
novel potential molecular markers were identified in ACC and BBC.  SOX10 was 
validated as a sensitive diagnostic marker for both cancers, and its expression was 
linked to normal and malignant myoepithelial/basal cells.  In ACC, BBC, and melanoma 
(MEL), SOX10 expression strongly co-segregated with the expression of ROPN1B, 
GPM6B, COL9A3, and MIA.  In ACC and breast cancers, SOX10 expression negatively 
correlated with FOXA1, a cell identity marker and major regulator of the luminal breast 
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subtype.  Diagnostic significance of conserved elements of the SOX10 signature (MIA, 
TRIM2, ROPN1, and ROPN1B) was confirmed in BBC cell lines.  SOX10 expression in 
ACC and BBC appears to be part of a highly coordinated transcriptional program 
characteristic of cancers with basal/myoepithelial features.  Comparison between 
ACC/BBC and other cancers, such as neuroblastoma and melanoma (MEL), reveals 
potential molecular markers specific for these cancers that are likely linked to their cell 
identity.  SOX10 as a novel diagnostic marker for ACC and BBC provides important 
molecular insight into their molecular etiology and cell origin.  Given that SOX10 was 
recently described as a principal driver of MEL, identification of conserved elements of 
the SOX10 signatures may help in better understanding of SOX10-related signaling and 
development of novel diagnostic and therapeutic tools. 
II.2.2 Introduction 
Adenoid cystic carcinoma (ACC) of the salivary gland, the second most frequent 
salivary cancer, is notorious for neural or perineural invasion and late recurrence.264  
When compared with salivary mucoepidermoid and head and neck squamous cell 
carcinomas, ACC overexpressed a large cluster of neuronal genes grouped around 
TrkC/NTRK3, a tyrosine kinase neurotrophic receptor associated with neurogenesis and 
cancer.200  This observation suggested, for the first time, that ACC aberrantly expresses 
genes involved in neural stem cell differentiation.  ACC was also found to express 
neurotrophin-3 (NT-3/NTF3), the TrkC ligand, suggesting that activation of TrkC through 
an autocrine signaling loop may contribute to tumor growth and dissemination. 
Ectopic expression of TrkC revealed that NT-3/TrkC signaling activates Ras, Akt, 
and Erk1/2 and promotes tumorigenic and aggressive behaviors, including increased 
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motility, chemotaxis, invasion, and growth in soft agar.200  To further characterize the 
activation of the gene expression program identified in ACC, focus was given to SOX10.  
SOX10 was of particular interest because of its roles as a marker of neural crest stem 
cells (NCSCs) and in the maintenance and migration of NCSCs.265-267  Remarkably, 
TrkC and SOX10 may be functionally linked, as inactivating mutations in NTRK3, NTF3, 
and SOX10 were identified as independent drivers of Hirschsprung disease,212, 213, 268, 
269 a genetic condition linked to the inability of NCSCs to migrate, differentiate, and 
develop into the enteric nervous system.270 
In addition to its role in neural crest development, SOX10 has also been 
identified as a driver of melanoma (MEL) progression, a cancer that develops from 
melanocytes that are neural crest derivatives.182  In this study, overexpression of 
SOX10 in ACC was identified and SOX10 was established as a sensitive ACC marker.  
Using available public data sets, a SOX10 gene signature was identified in basal-like 
breast carcinoma (BBC) and compared to the SOX10-centric signature in ACC.  BBC is 
perhaps the least understood breast cancer subtype that largely overlaps with triple-
negative breast cancers (TNBCs), lacks obvious molecular markers, and has no 
effective targeted therapeutic approach.271, 272  Together, these data suggest that a 
large portion of ACC and BBC may share neurologic signaling pathways associated 
with SOX10, which is also activated in MEL, and that these molecular similarities are of 
potential therapeutic importance. 
II.2.3 Materials and methods 
II.2.3.1 Head and neck cancer specimens.  Original expression array data were 
obtained on clinical specimens from 25 patients treated at Vanderbilt Ingram University 
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Medical Center: ACC (n=7), mucoepidermoid carcinoma (MEC, n=6), adenocarcinoma 
(n=2), and head and neck squamous carcinoma (n=10) (for clinical details, see 
(Ivanov et al, 2012)).  The validation set of ACC specimens (n=13) was obtained from 
the Salivary Gland Tumor Biorepository (MD Anderson Cancer Center, Houston, TX, 
USA). 
II.2.3.2 Cell lines.  A375, HCC38, HCC1569, MCF7, and T47D were obtained directly 
from ATCC (Manassas, VA, USA). MX-1 cells were purchased from the NCI tumor 
repository (Frederick, MD, USA). 
II.2.3.3 Expression array analyses.  Collection and processing of expression array 
data has been described previously.200  Analysis of data sets from public domains 
available from the ArrayExpress Archive (http://www.ebi.ac.uk/arrayexpress/) was 
performed using MEM (http://biit.cs.ut.ee/mem/index.cgi). 
II.2.3.4 Western blot analysis and antibodies.  Anti-human SOX10 antibodies (NBP1-
68983; Novus Biologicals, Littleton, CO, USA) and cell lysates produced from snap-
frozen VUMC and UVA specimens were used, as well as 13 additional specimens from 
MD Anderson Cancer Center specimens as described.200 
II.2.3.5 Immunohistochemical studies.  The salivary cancer tissue microarray (TMA, 
45 cores, 1mm diameter, 14 cases in triplicates) was assembled in the laboratory of Dr. 
Yarbrough.  Additional salivary cancer specimens (myoepithelial carcinoma, 
epimyoepithelial carcinoma, and basal cell adenoma) were obtained from the 
Department of Pathology, Yale School of Medicine.  The breast cancer TMA that 
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included triple-negative cases (YTMA-49-10, 0.6 mm core, n>300) was produced by the 
Yale Department of Pathology.  Mouse embryo slides (stage E15) were obtained from 
Zyagen (San Diego, CA, USA).  Staining with Sox10 antibodies (goat polyclonal, N-20; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed as described.273 
II.2.4 Results 
II.2.4.1 SOX10 is a novel and sensitive biological marker for ACC and other 
salivary cancers that originate from the acinar and intercalated duct regions  
Analyses of expression array data of grossly dissected ACC, MEC, and HNSCC 
tumors, revealed that SOX10 was specifically expressed in 17 of the 18 ACCs 
(including 11 ACC xenografts).  When compared to normal salivary gland tissue, 
SOX10 expression in primary ACC specimens was markedly increased (Figure 12A, ~5-
fold, ACC1; ~25-fold, ACC3).  Xenografted ACC tumors expressed a higher median 
level of SOX10 and a maximum of ~46-fold increase of SOX10 expression compared to 
normal salivary tissue (Figure 12A).  This high level of SOX10 expression was 
confirmed in a subset of ACC specimens at the protein level by immunoblotting (Figure 
12B).  SOX10 expression was determined in an independent collection of 13 clinical 
ACC specimens (gift of Adel El-Naggar, MD, Anderson Cancer Center) wherein SOX10 
was detected in all but one ACC, but was below the limit of detection in normal salivary 
specimens (Figure 12C).  IHC performed on tumor tissues revealed SOX10 staining in 
the majority of ACC tumor cells (Figure 12D).  Of note, specimens that demonstrated 
the lowest level of SOX10 expression also contained the lowest percentage of tumor 
cells in the specimen.  By IHC, SOX10 demonstrated intense nuclear staining as well as 
detectable cytoplasmic staining in ACC.  Conversely, only one MEC contained 
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detectable SOX10 expression (MEC1, Figure 12C), but the staining pattern for this 
tumor was quite different than seen in the ACC specimens, with only moderate 
nuclear/cytoplasmic staining (Figure 12E&F).  In addition to SOX10 expression in 
MEC1, this specimen was characterized as an outlier from other MECs in previous 
expression array analyses, and re-evaluation of the pathology (Dr. Manju Prasad, Yale 
University) for MEC1 classified this specimen as a carcinoma not otherwise specified 
(NOS) rather than a MEC. 
 As SOX10 is expressed in other tumors, such as melanoma, the potential value 
of SOX10 as a diagnostic marker beyond ACC was assessed.  Two cases of 
myoepithelial carcinoma, three cases of epithelial-myoepithelial carcinoma, and one 
basal cell adenoma were immunostained for SOX10.  In all cases, SOX10 staining was 
observed in >80% of cancer cells.  This staining was limited to the myoepithelial cells as 
confirmed in epithelial-myoepithelial carcinomas by expression of p63, calponin, and 
CK7 (data not shown). 
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Figure 12: SOX10 expression in ACC.   
(A) Expression array data show high SOX10 levels in most primary and xenografted ACC specimens 
compared to MEC, AD, HNSCC, and NSG tissues.  (B) Validation of expression array data by western 
blot.  (C) Expression of the SOX10 protein in 13 additional primary ACC specimens.  (D) 
Immunohistochemical localization of SOX10 expression in ACC1-7.  MEC2 stains negatively for SOX10.  
(E) Nuclear expression of SOX10 in ACC cells.  (F) Nuclear-cytoplasmic SOX10 expression detected in 
one out of six MEC specimens studied. 
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II.2.4.2 SOX10 is expressed in embryonic and differentiated salivary tissues 
Outside of cancer, SOX10 is recognized as a marker and principal regulator of 
neural crest stem cells (NCSC).273-275  To determine if SOX10 is expressed in 
developing and mature salivary gland tissue, SOX10 immunostaining of mouse E15 
embryonic tissue and human adult salivary tissue was performed.  In mouse embryos, 
SOX10 was expressed in presumptive acinar cells, but not the ductal epithelium, 
suggesting that SOX10 may be involved in the development of differentiation of acinar 
structures (Figure 13A).  In line with this observation, SOX10 was observed staining the 
nuclei of acinar and myoepithelial cells of the human adult salivary tissue (Figure 13B).  
As expected, Sox10 antibodies similarly stained the nuclei of melanocytes of normal 
skin and cutaneous melanoma (Figure 13C).  Together, these data indicate that SOX10 
has a role in the development and maintenance of salivary tissues, particularly those 
derived from neural crest.   
 
Figure 13: Immunohistochemical analysis 
of SOX10 expression.   
SOX10 Expression in (A) mouse embryonic 
and (B) human adult salivary glands.  The red 
arrow points to the developing duct, whereas 
the black arrow shows the acinus.  (C) 
Validation of SOX10 on sections of normal 
skin (left) and cutaneous MEL (right). 
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II.2.4.3 SOX10 expression in basal-type breast carcinoma 
To better understand the significance of SOX10 expression in human cancer, its 
expression was examined in 1764 publicly available cancer datasets using the 
Affymetrix U133 Plus 2.0 platform (http:// biit.cs.ut.ee/mem/).  This database utilizes a 
novel, noise-resistant rank aggregation and visualization algorithm developed by Adler 
et al.276 and Kolde et al.277 allowing for simultaneous comparison of gene expression 
across massive data sets to identify genes co-expressed with SOX10 (Figure 14A).  
Notably, breast cancer (22 studies, 10-80 < p < 10-30), melanoma, neuroblastoma, and 
glioma, demonstrate strong patterns of SOX10 co-expressed genes, but SOX10 and the 
associated gene signature were not seen in other cancers.  Delving into studies in 
which breast cancers were identified by molecular subtype, SOX10 expression was 
restricted to the basal-like subtype (Figure 14B).  Analysis of SOX10 expression in the 
basal subtype from two studies (E-GEOD-21653 and E-GEOD- 20711, n = 163) 
demonstrated that SOX10 was expressed in 72% of basal-like specimens (Figure 14B 
and data not shown).  When compared with luminal subtypes, the basal subtype 
expressed at least 16-fold higher levels of SOX10 (Figure 14C, p < 10-10).  The results 
of expression array analyses were confirmed by immunostaining of a TMA containing 
normal and malignant breast tissue (Figure 14D).  As seen in salivary tissue, normal 
breast tissue showed SOX10 immunostaining in the nuclei of basal/myoepithelial cells, 
although some luminal breast cells showed low expression of SOX10.  In the triple 
negative breast cancer (TNBC) specimens, which largely overlap with BBC, nuclear 
SOX10 expression was seen in >60% of malignant cells.  Taken together, these data 
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suggest that SOX10 is expressed in normal breast tissue primarily in the 
basal/myoepithelial cells as well as in basal like breast cancers.   
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Figure 14: Characterization of SOX10 signature in BBC.  
(A) Rank aggregation analysis identifies genes whose activity co-segregates with that of SOX10 in basal-
like breast cancer (BBC), melanoma (MEL), and neuroblastoma (NB).  Two breast cancer studies that 
stratify specimens by molecular subtypes are marked in a red frame.  (B) SOX10 overexpression in BBC.  
(C) The heat map for the E-GEOD-21653 study shows SOX10 signature expression in a great majority 
of basal-like specimens but not in other breast cancer subtypes. (D) Validation of SOX10 expression in 
normal (Left and left-center) and malignant (YTMA-49-10 TNBC cases 1840 and 1843; right-center and 
right, respectively) breast tissues. 
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II.2.4.4 Genes commonly co-expressed with SOX10 in ACC, BBC, and MEL  
In order to identify genes co-expressed with SOX10 across multiple tumor types, 
comparative analysis of the SOX10 gene signatures of ACC, BBC, and melanoma was 
performed.  For each cancer, the 160 genes most strongly co-segregating with SOX10 
were selected (Figure 15).  Comparing these lists revealed substantial overlap with ACC 
and BBC having 24 common genes (15%), BBC and melanoma had 17 common genes 
(~11%), and ACC and melanoma had six common genes (~4%).  The lower overlap 
between SOX10 gene signatures in ACC and melanoma may, in part, be due to SOX10 
in melanoma functioning primarily through MITF, which is not associated with ACC.  
Some of the genes co-expressed with SOX10 are markers of poor prognosis in 
melanoma (MIA,278 S100A1,279, 280 S100B,278, 280 and SHC4/RaLP281), BBC (FABP7,282 
FZD7,283 and MFGE8284) and ACC (FABP7)114 suggesting that SOX10 may be driving 
gene expression that correlates with aggressive or resistant phenotypes; however, the 
mechanistic and clinical significance of many of the signature genes remains to be 
explored including ROPN1B, GPM6B, and COL9A3, which co-segregated with SOX10 
in all three tumor types.   
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Figure 15: Common elements of SOX10 signatures in ACC, BBC, and MEL.  
ROPN1B, COL9A3, GPM6B, and MIA are strongly co-expressed with SOX10 in all three cancers.  This and other overlaps 
contain prospective clinical targets, several of which have been identified as clinically significant (underlined). 
 
81 
 
II.2.4.5 SOX10 signature is recapitulated in BBC cell lines 
To validate in silico findings, expression of SOX10 signature elements was 
examined in A375 melanoma, luminal breast, (MCF, T47D) and basal-like (HCC38, 
HCC1569, and MX-1) breast cancer cell lines.  Melanoma and BBC cells expressed 
SOX10 and several of its previously identified co-expression partners (MIA, TRIM2, 
ROPN1, and ROPN1B), whereas estrogen receptor (ESR1)-positive luminal MCF7 and 
T47D cell lines expressed only limited amounts of TRIM2 and ROPN1B with little or no 
detectable expression of SOX10 and MIA (Figure 16).   
 
Figure 16: Expression of SOX10 
signature components in MEL and 
BBC cell lines. 
End-point RT-PCR shows that MEL 
and BBC cell lines recapitulate the 
expression of SOX10 and elements of 
its signature, whereas ESR1-positive 
luminal breast cancer cell lines are 
negative for these genes. 
II.2.4.6 Genes whose expression negatively correlates with SOX10 expression in 
breast and salivary cancers 
To further explore SOX10 in breast cancer, correlation analysis was performed 
on the TCGA Invasive Breast Carcinoma dataset (Agilent mRNA expression 
microarrays, n = 547).285  This analyses identified FOXA1, ESR1, GATA3, XBP1, and 
CA12 as top-rank genes whose expression negatively correlated with SOX10 (data not 
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shown).  Expression of FOXA1 had the strongest negative correlation with SOX10, 
which was confirmed through analysis of E-GEOD-21653 BBC data set (Figure 17A), as 
well as analyses of the ACC expression array200 data set (Figure 17B).  The opposing 
expression of FOXA1 and SOX10 was consistent with reports that FOXA1 supports 
luminal breast cancer morphology286 and suppresses the basal-like phenotype.287   
Additionally, FOXA1 cooperates with ESR1 as a pioneer factor that maintains luminal 
identity in breast cancer and is required for ~50% of ESR1's activity.288  Pioneer factors 
are chromatin remodelers with the capacity to modulate cellular identity by defining the 
genomic regions accessible for other transcription factors.289  In addition to FOXA1, 
three other genes identified as negatively correlating with SOX10: GATA3, XBP1, and 
CA12 are each linked to the ESR1 and FOXA1 activities.286, 290-292  Taken together, 
these data indicate that expression of SOX10 and FOXA1 are largely mutually exclusive 
in breast and salivary cancers and that their expression is linked with distinct molecular 
subtypes. 
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Figure 17: Mutually exclusive expression of SOX10 and FOXA1 in breast and salivary cancers.  
(A) Heat map for the E-GEOD-21653 study and (B) expression array data on head and neck cancers show inverse SOX10 and 
FOXA1 expression in ACC and breast cancer, respectively. 
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II.2.5 Discussion 
The transcriptional factor SOX10 appears to support stem-like properties in 
normal tissues and cancer cells.  In normal tissue, SOX10 maintains stem cells in their 
undifferentiated state by preventing differentiation,237, 293, 294 whereas in MEL it serves 
as a marker of the stem-like CD271-positive cells.180  In ACC, as was previously 
demonstrated,200 SOX10 expression correlates with the neural stem markers TrkC, 
MAP2, SALL2, and SLITRK6.  In this study, SOX10 was established as a novel and 
sensitive ACC marker, which is expressed normally during salivary gland differentiation 
and is markedly up-regulated in a great majority of ACC cells.  This is similar to the 
trend seen in differentiating melanocytes and melanoma suggesting that SOX10 may 
function similarly in development of these diseases.  These studies also characterize 
SOX10 as a marker of BBC, a molecular subtype of breast cancer that lacks expression 
of estrogen, progesterone, and HER2 receptors (human epidermal growth factor 
receptor 2).295  As with ACC, BBC express basal cytokeratins296 and other genes linked 
to myoepithelial cells.297  The diagnostic value of SOX10 in BBC was confirmed by 
others.298  Unlike TrkC, which is highly specific for the myoepithelial cells/cancers of 
salivary gland and myoepithelial cells of breast tissue, SOX10 expression in salivary 
tissue was not restricted to the myoepithelial cells and tumors that show myoepithelial 
differentiation, but was also expressed in acinar cells, acinic tumors, and, occasionally, 
in the basal cells of the intercalated duct (data not shown).  Thus, SOX10 has a broader 
specificity than TrkC and may be helpful for the diagnosis of salivary cancers that 
originate from the acinar and intercalated duct areas of the salivary gland. 
85 
 
Characterization of SOX10 as a marker of both ACC and BBC supported the 
hypothesis that cancer cells hijack the inherent plasticity of normal stem cells.299  These 
studies may stimulate examination of the therapeutic and biological importance of 
SOX10 expression.  These novel potential markers and targets within SOX10 co-
expressed genes, once validated, may significantly increase the accuracy of FNA 
diagnosis in ACC and BBC.  Importantly, some SOX10 co-expressed genes have been 
validated as diagnostic and prognostic markers in cancer. 
Although SOX10 activity in MEL is essential for cell survival and growth,182 
targeting of transcription factors is challenging.  As SOX10 expression in each of three 
cancers appeared to be part of a highly coordinated expression profile containing 
hundreds of genes, a better understanding of molecular mechanisms, signaling 
pathways, and critical drivers that orchestrate such expression may provide a more 
efficient and broader means for tumor suppression.  As was shown, the overlaps 
between SOX10 gene signatures can identify common elements of the SOX10 network.  
Remarkably, two out of four genes that were consistently co-expressed with SOX10, 
GPM6B, and COL9A3 (Figure 15) have been previously reported to bind EGFR,300 a 
commonly recognized BBC marker and regulator.301  Thus, it would be interesting to 
explore the possible involvement of this receptor in SOX10 signaling.  Two of the 
closest SOX10 co-expression partners are ROPN1B and MIA.  Although little is known 
about ROPN1B, its function is most likely mediated through its R2D2 motif, which is 
implicated in cAMP-dependent PKA signaling,302 and PKA activity is implicated in 
melanocyte proliferation.303  It is essential to investigate the ROPN1B role in ACC and 
BBC.  Unlike ROPN1, the melanoma inhibitory activity protein (MIA) is a well-
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established diagnostic and prognostic serum marker and therapeutic target in 
melanoma;304-307  however, its link with SOX10 has not been previously established.  
Studies on serum derived from ACC and BBC patients are warranted in order to assess 
the clinical value of MIA in these cancers. 
Overall, these findings highlight previously unrecognized transcriptional networks 
and signaling pathways related to SOX10 expression in various cancers.  This work 
may stimulate further studies to identify common and cancer type-specific biomarkers 
and prospective therapeutic targets whose expression strongly co-segregated with 
SOX10. 
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II.3 Co-activation of NOTCH1 and SOX10 in Adenoid Cystic Carcinoma Stimulates 
CD133+ Cells with Neural Stem Properties  
Adapted from manuscript published in Cell Signaling.308  
II.3.1 Abstract 
  While existence of cancer stem cells (CSC) in adenoid cystic carcinoma (ACC) 
has been hypothesized, lack of assays for their propagation and uncertainty about 
molecular identify or markers prevented their characterization.  Previous studies 
supported expression of neural stem cell markers in ACC.309  Here, we identified a 
subpopulation of cells in ACC with properties of CSC, characterized their behavior and 
identified critical signaling pathways that support their propagation.  In order to isolate 
CSC from ACC and characterize them, ROCK inhibitor-supplemented cell culture 
techniques were optimized.  Immunomagnetic cell sorting and in vitro/in vivo assays 
were used to determine CSC viability and tumorigenicity.  CD133 was identified as a 
marker of a subpopulation of ACC cells that preferentially expressed NOTCH1 and 
SOX10, formed spheroids, and initiated tumors in nude mice.  NOTCH1 was activated 
only in CD133-positive (CD133+) cells, and these cells had the ability to generate 
CD133-negative (CD133-) cells.  On the other hand, CD133- cells preferentially 
expressed JAG1 and neural differentiation factors: NR2F1, NR2F2, and p27Kip1.  Single 
depletion of NOTCH1, SOX10, or their common effector FABP7, resulted in decreased 
expression of all three proteins.  Loss of NOTCH1, SOX10, or FABP7 inhibited 
spheroidogenesis and induced cell death in CD133+ cells, suggesting that they were 
essential for CSC maintenance.  Downstream effects of FABP7 knockdown included 
suppression of a broad spectrum of genes involved in proliferation, ribosome 
biogenesis, and metabolism.  Among proliferation-linked NOTCH1/FABP7 targets SKP2 
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and its substrate p27Kip1 were identified.  NOTCH inhibition using a -secretase inhibitor, 
DAPT, selectively depleted CD133+ cells, suppressed SKP2, induced p27Kip1, inhibited 
ACC growth in vivo, and sensitized CD133+ ACC cells to radiation.  These results 
established that ACC contains a previously uncharacterized population of CD133+ cells 
with neural stem properties that are dependent on SOX10, NOTCH1, and FABP7.  
Sensitivity of these cells to Notch inhibition and their dependence on SKP2 offer new 
opportunities for targeted ACC therapies. 
II.3.2 Introduction 
  Adenoid cystic carcinoma (ACC) accounts for nearly one quarter of malignant 
neoplasms of the salivary gland and is a slow-growing yet unpredictable tumor with a 
propensity for insidious growth, perineural invasion, and distant metastases.  Three 
major histological subtypes of ACC are distinguished in morphological features: tubular, 
cribriform, and solid.  Although variation in clinical presentation of these types has been 
reported, all three patterns are neuroinvasive and show extremely high rates of 
recurrence.  Treatment for ACC is currently limited to surgery with or without radiation, 
consistent with limited insight into its molecular drivers.33  ACC has a high recurrence 
rate and dismal survival in part because of its intrinsic resistance to radio- and 
chemotherapies.310  Existence of cancer stem cells (CSC) in ACC has been 
proposed,309 but their molecular identity has remained elusive due to difficulties with 
ACC culture and the inability to identify stemness markers in these tumors.  
Development of targeted therapies for ACC has been further complicated by lack of 
reliable in vitro models, as there are currently no ACC cell lines available from 
centralized resources.  Six previously created and shared cell lines were proven to be 
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grossly contaminated or misidentified, invalidating years of work and publications that 
used these lines.129 
 Recently, characterization of differentially expressed genes in primary salivary 
tumor specimens, ACC patient-derived mouse xenografts (PDX), head and neck 
squamous cell carcinoma, and normal salivary gland tissue228 revealed a gene profile in 
ACC indicating neural stem signaling was active.  ACC are rare tumors; therefore, 
subcutaneous PDX models that recapitulate basic ACC features, such as histologic 
appearance of the original tumor, characteristic t(6;9) translocations, and gene 
expression patterns were used as a reliable source of tumor tissue for study.200, 228  
While there are drawbacks of PDX models including relatively high maintenance costs 
and lack of interactions with the immune system, advantages of PDX models include 
preservation of tumor cell heterogeneity within a three-dimensional tumor.  Many stem 
cell-centric cancer studies heavily rely on PDX models to maintain CSC 
subpopulations.311-314  Analysis of clinical and PDX data revealed expression of 
neuronal genes and stem cell markers intrinsic to ACC, suggesting aberrant activation 
of a transcriptional program that controls neural stem cells (NSC).  This finding was 
supported by the association of ACC with high expression of SOX10, a major 
transcriptional regulator and molecular marker of normal and malignant cells that 
originate from the neural crest.182, 266  Expression profiles of many tumor types revealed 
that SOX10 gene signatures were present in basal-like breast carcinoma, melanoma, 
neuroblastoma, and glioma.263 
 Here, a ROCK inhibitor-based approach was optimized to support propagation of 
stem cells315, 316 and produce sustainable ACC cell cultures that maintained cell lineage 
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identity.  Using this new approach, a previously unknown population of tumorigenic 
CD133+ cells that expressed SOX10, NOTCH1, and activated intracellular NOTCH1 
domain (N1ICD) was identified and characterized.  NOTCH1 activity in CD133+ ACC 
cells was supported by expression of NOTCH1 targets including SKP2, an E3 ubiquitin 
ligase that targets p27Kip1 for degradation and stimulates proliferation of CSC.317, 318  On 
the other hand, CD133- cells expressed JAG1 (a Notch ligand), p27Kip1 (a cyclin-
dependent kinase inhibitor), and neural differentiation genes NR2F1 and NR2F2.  As 
Notch signaling is linked to cell proliferation and radiation resistance,319, 320 the effect of 
NOTCH1 inhibition on CD133+ cell survival and radiation sensitivity was investigated.321  
This work identified a population of stem-like cells and delineated principal signaling 
pathways in ACC that may be used in the near future for ACC treatment. 
II.3.3 Materials and Methods 
II.3.3.1 PDX and primary tumor specimen.  PDXs of ACC in nude mice have been 
previously described.200, 228  One clinical ACC specimen was collected from the Smilow 
Cancer Center at Yale New Haven Hospital (HIC# 1206010419). 
II.3.3.2 Tissue processing.  5-10 mg of fresh or cryopreserved (90% FBS and 10% 
DMSO) tumor tissue was rinsed once with PBS, 70% EtOH, 100X Anti-Anti (GIBCO), 
twice with PBS containing 1:500 ceftazidime, and minced.  Digestion was performed at 
37ºC for 1-2 h with occasional agitation in 3 mL of DMEM media (10% FBS, 1x 
Pen/Strep, 1x L-Glutamine) supplemented with 1 mL of Dispase (BD Biosciences, San 
Jose, CA), 30-150 µL hyaluronidase (Sigma, St. Louis, MO), and 30-150 µL 
collagenase (Roche, Indianapolis, IN).  Digested tissue was collected at 1,500 rpm for 3 
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min., rinsed with PBS, re-centrifuged, transferred into 3 mL of F+Y media (see below), 
and filtered using a 100 µm cell strainer.  Tumor cells were cultured in a CO2 incubator 
with irradiated 3T3-J2 cells or conditioned media derived from these cells (see below). 
II.3.3.3 Cell culture.  3T3-J2 feeder cells were grown as described.316  To create 
conditioned media, irradiated 3T3-J2 cells were incubated in a T-150 flask 
supplemented with 30 mL of DMEM media for 4 days.  Media was filter-sterilized and 
then mixed in a 1:4 ratio with F+Y media.  
II.3.3.4 Real-time RT-PCR.  RNA was isolated from frozen cell pellets of cells using 
RNeasy kit (Qiagen, Valencia, CA).  cDNA was generated using Bio-Rad iScript 
Reverse Transcriptase kit.  Real-time PCR was performed using iQ SYBR Green 
Supermix and CFX96 real-time detection system (Bio-Rad, Hercules, CA).  
II.3.3.5 Western blot analysis.  The following antibodies were used: SOX10 (Abcam, 
ab155279), NOTCH1 (Cell Signaling, #3608), FABP7 (Cell Signaling, #13347), cleaved 
NOTCH1 (Cell Signaling, #4147), p27Kip1 (Cell Signaling, #2552), SKP2 (Cell Signaling, 
#4313), β-actin (Santa Cruz, sc-47778), and GAPDH (Santa Cruz, sc-25778).  Pre-cast 
gels, Rapid Transfer Turbo-blot System, and gel imaging software were from Bio-Rad.  
II.3.3.6 Microsatellite analysis.  For cell line authentication, Short Tandem Repeat 
(STR) analysis as recommended by ATCC https://www.atcc.org/~/media/PDFs/ 
Technical%20Bulletins/tb08.ashx was performed using Promega GenePrint 10 STR 
analysis PCR kit with fluorescent tagging.  PCR products were analyzed on Applied 
Biosystems 3730xL DNA Analyzer at the Yale Keck Facility and data processed using 
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GeneMapper 3.7 (Applied Biosystems) software.  The results were compared to STR 
databases (http://www.cstl.nist.gov/strbase/, http://www.dsmz.de/services/services-
human-and-animal-cell-lines/online-str-analysis.html).  
II.3.3.7 Flow cytometry.  Cells were collected and incubated with CD133-PE antibody 
(Miltenyi) for 10 minutes.  Fluorescence-activated cell sorting (FACS) was performed to 
determine percentage of CD133+ cells using a FACS Caliber BD machine.  Data 
analysis performed using Flowing Software version 2.5.0. 
II.3.3.8 Cell sorting.  For separation of CD133+ and CD133- cells from cultured cells 
and grafted tissue, CD133 Tumor Tissue MicroBead Kit from Miltenyi (San Diego, CA) 
was used according to the manufacturer’s protocol.  
II.3.3.9 Tumorigenicity assays.  All mouse experiments were performed in accordance 
with NIH national guidelines and were approved by Yale University IACUC.  Athymic 
NCr-nu/nu mice purchased from NCI-Frederick (Frederick, MD) were used for 
subcutaneous injections in the flanks with a specified number of viable tumor cells.  
II.3.3.10 Spheroidogenesis and spheroid viability assays.  For spheroid studies, 
approaches as previously described were performed.322  Briefly, spheroid formation and 
disintegration were studied in six-well plates with or without DAPT (Eli Lilly, GSI-IX) from 
Selleckchem, Houston, TX, or DMSO control.  At 24 hour intervals, three separate 
representative digital images per well at 4X magnification were used to quantify 
spheroid number by direct visual counting. 
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II.3.3.11 Immunofluorescence staining. Cells were plated onto glass slides at a 
density of 25,000-30,000, incubated for 24 h, washed twice with PBS, and fixed with 3-
4% paraformaldehyde at RT for 30 min.  Cells were permeabilized with 0.15% Triton X-
100 in PBS for five minutes, washed twice, and blocked with 3% BSA for 30 minutes.  
Incubation with primary antibodies diluted in 3% BSA was done at 40C overnight with 
subsequent washing once with PBS and once with 3% BSA.  The following antibodies 
were used: SOX10 (Abcam, ab155279), FABP7 (D8N3N), NOTCH1 (D1E11), and 
SKP2 (#4313) from Cell Signaling, JAG1 (C-20) and NR2F1 (sc-74561) from Santa 
Cruz, NR2F2 (H7147) from Parsons Proteomics, and AlexaFluor secondary antibodies 
from Life Tech. 
II.3.3.12 Immunohistochemical staining.  The following antibodies were used: 
cleaved NOTCH1 (Val1744) antibodies from Cell Signaling (Danvers, MA), SOX10 
antibodies from Cell Marque (Rocklin, CA), and FABP7 antibodies from Abcam 
(Ab32423, Cambridge, MA). 
II.3.3.13 Proliferation assays.  Cells were cultured in 96-well black clear bottom plates 
and treated with DAPT versus control (DMSO).  After cells were grown for 24-96 hours, 
viable cells were assayed using the Cell Titer Glo system (Promega).  
II.3.3.14 Cell cycle analysis.  Cells were fixed in 70% cold ethanol and stained with 
propidium iodide.  A FACS Caliber BD machine was used and data analysis performed 
using Flowing Software version 2.5.0. 
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II.3.3.15 Cell death assay.  Cells were incubated for 10 minutes with CD133-FITC 
antibody (Miltenyi) as well as Annexin V antibody and 7-AAD DNA stain (Annexin V:PE 
apoptosis detection kit I, BD Biosciences).  A FACS Caliber BD platform was used and 
data analysis was performed using Flowing Software version 2.5.0. 
II.3.3.16 Radiosensitivity assay.  Cells plated in T-25 flasks were irradiated using Mark 
I Cesium-137 irradiator, incubated for 48 hours in the presence or absence of DAPT, 
and stained with CD133-PE antibody.  FACS was performed to determine percentage of 
CD133+ cells.  Statistical differences in tumor volume were determined using a two-
tailed t-test.  
II.3.3.17 DAPT studies on ACC xenografts.  In vivo efficacy of DAPT was evaluated in 
an Accx11 xenograft model generated via subcutaneous injection of 106 cultured 
Accx11 cells.  Tumor cell-injected mice were randomized into control (vehicle-injected) 
and experimental (DAPT in corn oil) groups 15 days after cell injection.  DAPT was 
given via intraperitoneal (i.p.) injection at 50 mg/kg, following a 3/4 injection schedule 
(three days of treatment/four days rest) for 35 days.  To assess DAPT toxicity, animals 
were observed daily and weighed weekly using a digital scale.  To assess DAPT 
efficacy, tumor dimensions were measured weekly by a digital caliper and data 
including individual and mean estimated tumor volumes (mean TV ± s.e.m.) were 
recorded for each group.  Tumor volume was calculated using the formula TV = width2 × 
length × 0.52.  Statistical differences in tumor volume were determined using a two-
tailed t-test.  
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II.3.4 Results 
II.3.4.1 Generation and validation of primary cell cultures from ACC tissue 
 As indicated by the absence of available ACC cell lines, ACC cells are difficult to 
culture using standard techniques (our unpublished observations).  Validated PDX 
models were used as a source of ACC tissue to develop new culture techniques, since 
primary tumor tissue is scarce.200, 228  A recently described conditional reprogrammed 
cell culture (CRC) protocol316 was optimized to produce intermediate and long-term cell 
cultures from five ACC xenografts and one primary ACC tumor (Fig. 18A&B). Short-
tandem repeat DNA profiling as recommended by ATCC,323 was performed to 
determine provenance of newly created cell cultures (Table 3).  
 Previous expression analyses of ACC identified markers associated with neural 
stemness including TrkC/NTRK3, SOX10, NOTCH1, and FABP7.200, 263  Reassuringly, 
all ACC cell cultures expressed all four neural stem genes (Figure 18C), recapitulating 
expression of these genes in clinical ACC specimens and the parental PDXs (Figure 
19).  However, cultures of normal salivary gland cells did not express FABP7 and had 
levels of SOX10 and NTRK3 that were at the limit of detection.  Thus, the optimized 
ROCK inhibitor and cell feeder-based protocol proved to be an effective solution to the 
ACC cell culture problem.  Continued use and optimization of this technique may 
significantly advance translational ACC research. 
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Figure 18: Clinical, cytological, and molecular properties of ACC cell cultures.  
(A) Features of ACC cell cultures as well as PDXs (Accx) or tumor (Acc33) from which cultures were 
derived.  m, metastases.  (B) Low and high magnification brightfield images of cultured ACC cells at 
indicated passages for Accx5m1, Accx11, Accx19, and Acc33.  (C) Real-time PCR quantification (qRT-
PCR) of gene expression for SOX10, NOTCH1, FABP7, NTRK3/TrkC, and PROM1/CD133 in cultured 
ACC cells compared to cultured cells isolated from normal salivary gland (NSG).  In all qRT-PCR 
experiments, expression is normalized to β-actin and standard error bars representative of at least two 
independent experiments.  
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Figure 19: Expression of SOX10, NOTCH1, FABP7, and CD133 in ACC tumor specimens from patients (P) and PDX (X).  
Comparison is based on previously produced Affymetrix data.200   
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Sample 
Source of 
cells/tumors 
TH01 D21S11 D5S818 D13S317 D7S820 D16S539 CSF1PO Amelogenin 
ACCX2 Xenograft 10 28.3, 31, 32 10.1, 11.1 11, 12, 15 11 11, 12.1 11, 12 - 
Accx2 Culture 10 
27.3, 28.3, 
30.3, 31.2 
10.1, 11.1, 
12.3 
11, 13, 14 8, 11 10, 11, 12.1 
6.3, 11, 
12 
X 
ACCX5M1 Xenograft 9.1, 10 
28, 29.3, 32, 
32.1 
12.3 10, 14 7, 11 9, 11 9.3, 11 X, Y 
Accx5M1 Culture 9.1, 10 29.3, 32.1 12.3 11, 14 7, 11 9, 13.1 9.3, 10.3 X, Y 
ACCX11 Xenograft 6.1, 10 28.3, 31.1 11.1 13, 14, 8, 9.1 11, 12.1, 10, 12 X 
Accx11:9 Culture 6.1, 10 28.3, 31.1 11.1 13, 14, 8, 9.1 11, 12.1, 10, 12 X 
ACCX11:9p:0 
Xenograft 
from Cx 
6.1, 10 28.3, 31.1 - 13, 14, 8, 9.1 11, 12.1, 10, 12 X 
ACCX11 
CD133- 
Xenograft 
from Cx 
6.1, 10 28.3, 31.1 11.1 13, 14 8, 9 11, 13 10, 12 X 
ACCX11 
CD133+ 
Xenograft 
from Cx 
6.1, 10 
28.3, 30, 
31.1 
11.1 13, 14 8, 9 11, 13 10, 12 X 
ACCX14:9 Xenograft 8, 10, 13.3 28.3 10.1, 11 15 9, 10 12.1 11, 12 X 
Accx14:9 Culture 8.3, 10 28.3 10.1, 11.1 14 9.1, 10 11, 12.1 11, 12 X 
ACCX19 Xenograft 7.1, 8 27.3 12.3 13, 15 8, 11 10, 11 6.3, 12 - 
Accx19 Culture 7.1, 8 27.3 12.3 13, 15 8, 11 10, 11 6.3, 12 - 
ACCX29 Xenograft 6.1, 7.1 29.3, 31 10.1, 11 13, 14 10 9, 11 12 X 
Accx29 Culture 6.1, 7.1 29.3, 31.1 10.1, 11.1 13, 15 9.3, 9, 11 12, X 
ACC33 Patient tumor 9.1, 10 28.3, 29.3 9 11, 15 9.3, 11 11, 12.1 11, 14 X 
Acc33 Culture 9.1, 10 28.3, 29.3 9 10, 14 10, 11 11, 12.1 11, 14 X 
 
Table 3: Short-tandem repeat pattern of ACC cell cultures and parental xenografts. 
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II.3.4.2 Isolation and characterization of previously unrecognized CD133+/ 
SOX10+/NOTCH1+ ACC cells 
Expression of the key neural stem cell marker, SOX10, in ACC and other cancer 
types that originate from neural crest200, 263 suggested that either all ACC cells may 
express this stem cell marker, or that a subpopulation of ACC cells with neural stem 
properties may exist.  To begin distinguishing these possibilities, cell surface markers 
co-expressed with SOX10 in ACC were identified.  CD133/PROM1 (hereafter, CD133), 
a CSC cell surface marker used in neural cancer stem cell isolation,324 was expressed 
in nearly all clinical ACC specimens and PDXs (Figure 19).  While CD133 expression 
was recently reported in ACC,325 there have been no published attempts to isolate and 
characterize CD133+ ACC cells.  Interestingly, CD133 was expressed in all ACC cell 
cultures that were generated but not in cultured normal salivary epithelial cells (Figure 
18C), suggesting that it may be used as a tool for CSC isolation. 
To begin analyzing CD133-expressing ACC cells, a robustly proliferating and 
spheroid-forming culture, Accx11 (Figure 18A&B), was the initial focus.  Accx11 was 
derived from a xenograft of a grade 3 ACC that is distinguished by solid histology and 
poor prognosis.326  FACS analysis of Accx11 cells revealed high CD133 expression in a 
mean of 12% of cells (Figure 20).  CD133+ and CD133- fractions enriched by magnetic 
activated cell sorting (MACS) with CD133 antibody coupled beads produced more than 
50-fold enrichment of CD133 expression (Figure 21A).  Excitingly, CD133+ cells 
expressed at least 25-fold higher levels of SOX10, NOTCH1, and FABP7 as compared 
to CD133- cells, suggesting that expression of these genes co-segregated with cell 
surface expression of CD133 (Figure 21B).   
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Figure 20: FACS analysis of Accx11 cells 
stained with PE-conjugated CD133 antibody.  
CD133+ cells (red) comprise ~12.4% of the bulk 
population.  
 
 
After separation, CD133+ cell cultures generated both spheroid-forming and 
tightly adherent cells.  Cultured CD133- Accx11 cells, however, remained adherent and 
were not able to produce either CD133+ cells or spheroids (data not shown).  These 
data suggest that CD133+, but not CD133- cells, express key stem cell markers and are 
capable of asymmetric division recreating both CD133+ and CD133- cell populations.  
To further explore signaling in CD133+ cells, expression of SCRG1, PLP1, MIA, SHC4, 
and TTYH1 previously linked to the SOX10 neural gene signature in ACC263 was 
investigated.  Remarkably, without exception these genes were more highly expressed 
in CD133+ ACC cells compared to bulk or CD133- cells (Figure 21B).  In light of the 
association of these genes with cancers of neural stem cell origin,281, 327-329 their 
selective expression in CD133+ ACC supported the existence of a stem cell 
subpopulation in ACC.  
 Activation of Notch is a common feature of non-cancer neural stem cells and 
CSC of neural origin.330  Immunoblotting revealed high expression of NOTCH1 and 
cleaved/activated NOTCH (N1ICD) in CD133+, but not in CD133- or unsorted cells, and 
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confirmed high expression levels of SOX10 and FABP7 in CD133+ cells (Figure 21C).  
In line with Notch activation, its canonical targets HEY1, HEY2, and MYC were 
predominantly expressed in CD133+ cells (Figure 22D).  
In order to determine if other ACC cultures harbored similar cell populations, 
Accx19 cells (Figure 19A-C) were examined.  In agreement with lower expression levels 
of SOX10, NOTCH1, and FABP7, the percentage of CD133+ cells in Accx19 determined 
by FACS analysis was lower than in Accx11 comprising <8% of total cells (data not 
shown).  MACS separation of Accx19 cells produced 2.5-3-fold enrichment of CD133 
expression in CD133+ cells compared to CD133- cells.  In CD133+ Accx19 cells, 
expression of NOTCH1, SOX10, and FABP7 was similarly enriched (data not shown).  
Overall, these data supported the existence in ACC of a previously unknown population 
of SOX10-positive CD133+ cells with activated NOTCH1.  
II.3.4.3 CD133 ACC cells express neuronal differentiation genes NR2F1 and 
NR2F2, p27Kip1, and a Notch ligand, JAG1   
CD133-sorted cells were analyzed for expression of two orphan nuclear 
receptors whose expression is required for NSC differentiation, NR2F1 and NR2F2.331  
This comparison revealed markedly increased expression of both genes in CD133- cells 
(Figure 21E), suggesting that these cells may be more differentiated than CD133+ cells.  
Jagged-1 (JAG1), a canonical Notch ligand, is an essential component of Notch 
signaling, and in many cancers it is expressed not in stem cells but in supporting 
niches.332, 333  Interestingly, JAG1 expression was markedly higher (~11-fold) in CD133- 
Accx11 cells (Figure 21E).  Enhanced expression of NR2F2 and JAG1 was also 
observed in CD133- cells isolated from Accx19 cultures (data not shown). 
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p27Kip1 is a critical effector of neural differentiation, and in NSC NOTCH1 blocks 
p27Kip1 expression.334, 335  Given that NOTCH1 is preferentially activated in CD133+ cells 
and that CD133- cells express markers of neural differentiation, p27Kip1 expression in 
both fractions was analyzed.  Immunoblotting of unsorted and CD133- cells revealed 
significantly higher p27Kip1 levels compared to the CD133+ population (Figure 21F).   
Selective expression of NOTCH1 and its targets in CD133+ cells and JAG1 and 
NR2F1/2 in CD133- cells indicated that these ACC cell subpopulations may 
communicate via NOTCH1/JAG1 interaction (Figure 21G).  To begin dissecting 
differences and interaction between CD133+ and CD133- cells, cultures of mixed cell 
subpopulations, as indicated by loosely adherent cells/spheroids versus adherent 
Accx11 cells, were stained by immunofluorescence.  In agreement with RT-PCR and 
immunoblot data (Figure 21B&C), membrane CD133 and NOTCH1 staining was 
detected in cells associated with loosely adherent cells/spheroids, but not in the firmly 
adherent cell population (Figure 21H&I).  Similarly, SOX10 and FABP7 stained cells in 
loosely adherent cells/spheroids, while differentiation markers NR2F1 or NR2F2 were 
seen in adherent surrounding cells (Figure 21I-K).  Remarkably, NOTCH1-expressing 
cells within loosely adherent cells/spheroids were closely surrounded by adherent cells 
expressing membrane-localized Jagged-1 (Figure 21L).  Z stack images revealed that 
JAG1 and NOTCH1 were co-localized on the surface of these adjacent cells (Figure 
21L, see arrows) supporting NOTCH1/JAG1 communication and a signal-sending 
supportive role of JAG1-producing CD133- cells.  
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Figure 21: Isolation and characterization of CD133+ and CD133- cells in Accx11 culture.  
(A) qRT-PCR of CD133 expression in Accx11 cell fractions following magnetic-activated cell sorting (MACS).  (B) Expression analysis by qRT-
PCR of ACC-associated (SOX10 & FABP7) and NSC-associated (NOTCH1, SCRG1, PLP1, MIA, SHC4, & TTYH1) genes in MACS-sorted 
Accx11 cell fractions.  (C) Immunoblot analysis shows selective expression of SOX10, NOTCH1, activated intracellular domain of Notch-1 
(N1ICD), and FABP7 in CD133+ cells.  β-actin serves as a loading control.  (D) Expression analysis by qRT-PCR of Notch targets MYC, HEY1, 
and HEY2 in MACS-sorted Accx11 cell fractions.  (E) Expression analysis by qRT-PCR of JAG1 and neural differentiation markers NR2F1 and 
NR2F2 in MACS-sorted Accx11 cell fractions.  (F) Immunoblot analysis of CD133 fractions demonstrates CD133- cell-specific p27Kip1 expression.   
β-actin serves as a loading control.  (G) Molecular determinants of stem-like CD133+ cells and more differentiated CD133- cells.  (H-L) 
Immunofluorescence (IF) staining demonstrates great selectivity of CD133+ and CD133- cell markers and confirms spheroid-forming property of 
CD133+ cells. Z-stack images (L) show NOTCH1 and JAG1 co-localization at sites of spheroidal and non-spheroidal cell contacts (arrows). 
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II.3.4.4 CD133+ and CD133- populations identified in grafted ACC tissue 
In order to diminish the possibility that findings were the result of cell culture 
artifacts, the existence of CD133+ and CD133- cell populations was validated using PDX 
tissue derived from 5 ACC patients.  To this end, fresh PDX tumors were dissociated 
into cells, and CD133+ and CD133- populations immediately magnetically separated.  
CD133+ cells comprised from 21 to 65% of viable cells derived from xenografts (Figure 
22A) and real-time PCR revealed that these cells expressed higher levels of SOX10, 
NOTCH1, and FABP7, with a few exceptions (Figure 22B-E).  On the other hand, 
CD133- cells universally expressed higher levels of JAG1, while NR2F1 expression was 
more variable (Figure 22F&G).  These results mirrored the findings in cultured cells 
derived from ACCX11 and ACCX19 (Figure 21 and data not shown).  Collectively, these 
data confirmed the existence of two distinct cell populations in ACC marked by 
expression of either SOX10+/NOTCH1+/FABP7+/CD133+ or JAG1+/CD133- in ACC.  
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Figure 22: Isolation and characterization of CD133 fractions from ACC xenografts.  
(A) Variation in the percentage of CD133+ cells across ACC xenografts.  (B) qRT-PCR analysis of CD133 
expression confirms adequate separation of CD133+ and CD133- cells isolated from ACC xenografts.  
(C-E) Selectivity of SOX10, NOTCH1, and FABP7 to CD133+ cells isolated directly from ACC xenografts 
as confirmed by qRT-PCR.  (F-G) Selectivity of JAG1 and NR2F1 to CD133- cells isolated directly from 
ACC xenografts as confirmed by qRT-PCR. 
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II.3.4.5 Tumorigenicity of ACC cultures and dependency on CD133 status   
The ability of cultured ACC cells to initiate tumors was investigated via 
subcutaneous injections of 106 cells into flanks of nude mice.  Among ACC cultures 
tested to date, only Accx11 cells were tumorigenic in nude mice creating tumors with 
solid histology and an intervening stromal component similar to the parental patient 
tumor and PDX (Figure 23A).  Relative expression of CD133, SOX10, NOTCH1, and 
FABP7 was similar in the original PDX and in the tumor produced from injection of 
cultured cells (Figure 23B&C).   
In various cancers, CD133 expression defines populations of CSC with 
enhanced tumor-initiating properties.336  To investigate CSC properties of CD133-
expressing ACC cells, bulk Accx11 cells were magnetically sorted based on CD133 
expression and 104 cells injected subcutaneously into right (CD133+) and left (CD133-) 
flanks of three nude mice.  After 22 weeks, tumors were observed in three of three sites 
injected with CD133+ cells, but in none of three sites injected with CD133- cells.  At 32 
weeks, a single tumor formed at a site injected with CD133- cells.  Histologic evaluation 
of the parental ACCX11 tumor, tumors derived from CD133+ cell injections, and the 
single tumor from a CD133- cell injection revealed similar histologic appearance (data 
not shown).  Expression analyses of CD133, SOX10, NOTCH1, and FABP7 by qRT-
PCR and immunoblotting revealed expression of all markers in tumors derived from 
both CD133+ and CD133- cells (data not shown), suggesting that small amounts of 
CD133+ are trapped in the CD133- fraction or that injected CD133- cells can convert to 
CD133+ cells. 
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As experience with CD133 cell separation increased, it became apparent that a 
single round of separation using CD133 antibody conjugated to beads left detectable 
traces of CD133+ cells in the CD133- population reflecting technical limitations of this 
procedure.  Also, separation decreased viability of CD133+ cells more than CD133- 
cells, possibly due to the damage inflicted by elution of column-bound cells (data not 
shown).  To more adequately compare tumorigenicity of CD133+ and CD133- cells, a 
second round of magnetic separation was performed on the unbound cells to isolate a 
more pure CD133- population.  Following this double separation, 105 viable cells of each 
population were injected into the flanks of nude mice.  Tumors began to form at the 
sites of CD133+ injections as early as 6.5 weeks after injection.  By 13 weeks post-
injection, four of five CD133+ injection sites had distinct tumors while none of five 
CD133- injections showed signs of tumor formation (Figure 23D).  With a marked delay, 
two of five injection sites of CD133- cell injections formed small tumors with the earliest 
tumor developing at 19 weeks.  At 27.5 weeks, all of the five CD133+ injection sites 
formed tumors, while no additional tumors grew in CD133- injection sites.  Overall, these 
experiments demonstrated enhanced tumorigenicity of CD133+ cells compared to 
CD133- cells. 
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Figure 23: Tumorigenic properties of bulk and CD133-fractionated Accx11 cells.  
(A) Cultured bulk Accx11 subcutaneously injected in athymic nude mice produce tumors with histology similar to patient tumor and 
parental xenograft (H&E staining).  (B) CD133, SOX10, NOTCH1, and FABP7 expression by qRT-PCR confirms ACC identity of PDX 
and tumors generated from injection of bulk Accx11 cells.  (C) Immunoblot analysis confirms similar expression of SOX10, NOTCH1, 
and FABP7 in PDX and tumor formed from injected bulk Accx11 cells.  GAPDH serves as a loading control.  (D) Dot plot of tumor 
volumes 90 days after injection of 105 CD133- or CD133+ MACS-sorted Accx11 cells. 
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II.3.4.6 Interdependence between NOTCH1, SOX10, and their common effector 
FABP7 
Essential individual roles for SOX10 and NOTCH1 in neural stem cell 
maintenance are well established, and loss of Notch signaling decreases SOX10 
expression in neural progenitors.337, 338  FABP7 has recently been described as critical 
for proliferation and to prevent differentiation in neural progenitors.339  Given that 
SOX10, NOTCH1, and FABP7 are each implicated in neural stemness, their 
interdependence in ACC cells was explored.  Following individual depletions, 
expression of all three genes was measured by qRT-PCR and immunoblotting.  
Knockdown of SOX10 markedly decreased NOTCH1 expression, and similarly, 
depletion of NOTCH1 was associated with decreased SOX10 both at the mRNA and 
protein levels (Figure 24A&B), suggesting interdependence and functional cooperation.  
As expected, since FABP7 is a common NOTCH1/SOX10 target,122, 340 depletion of 
either NOTCH1 or SOX10 markedly suppressed FABP7 mRNA and protein levels.  
Depletion of FABP7 had less suppressive effects on NOTCH1 and SOX10 mRNA than 
did either NOTCH1 or SOX10 knockdowns.  At the protein level, FABP7 had no obvious 
effect on NOTCH1 expression while modestly decreasing SOX10 levels (Figure 
24A&B). 
 Individual roles of NOTCH1 and SOX10 in CSC and NSC survival are well 
established, but their co-operation via FABP7 has not yet been studied.  To begin 
exploring the role of FABP7 in adenoid cystic carcinoma signaling, it was depleted in 
Accx11 cells followed by gene expression profiling.  Analyses revealed that 1158 genes 
were downregulated (Table 4, 2-fold threshold), and KEGG pathway analysis 
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(http://bioinfo.vanderbilt.edu/webgestalt/) implicated these genes in cell cycle regulation, 
ribosome biogenesis, cell metabolism, and signaling pathways involved in these 
processes (Table 4 and data not shown).  Among these genes, 11 belonged to the 
Notch signaling network and 26 genes overlapped with the ACC SOX10 gene signature 
previously characterized.263  This observation further supported the feedback signaling 
from FABP7 to NOTCH1 and SOX10.  In addition, SKP2, a major NOTCH1 effector 
involved in the regulation of cell cycle and proliferation,341 was among 31 cell cycle 
progression and 11 NOTCH1-regulated genes downregulated by FABP7 knockdown 
(Table 4).  In summary, these data suggested that NOTCH1, SOX10, and FABP7 may 
be co-regulated in ACC, and that FABP7 may serve as a pro-survival NOTCH1 and 
SOX10 effector. 
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Pathway/Gene 
Signature 
# 
Genes 
Gene Name 
Statistics, 
p value 
Cell cycle 
31 ANAPC7, BUB1, BUB1B, CCNA2, 
CCNB2, CCND1, CCNE2, CDC20, CDC6, 
CDK1, CDK4, CDK6, CDKN2C, CHEK1, 
DBF4, MAD2L1, MCM2, MCM3, MCM4, 
MCM6, MYC, ORC5, PRKDC, PTTG1, 
SKP2, TFDP1, TFDP2, TGFB2, TTK 
2.19E-22 
Ribosome 
27 RPL0, RPL3, RPL4, RPL5, RPL6, RPL7A, 
RPL10, RPL10A, RPL13, RPL13A, RPL14, 
RPL15, RPL22, RPL23, RPL27A, RPL31, 
RPL35A, RPL37, RPS2, RPS3, RPS6, 
RPS7, RPS8, RPS15A, RPS20, PS21, 
RPS23 
1.08E-21 
Metabolic 
pathways 
82 ACAT1, ACO1, ACOX1, ACY1, ADI1, 
ADSL, GPS, AHCY, ALDH5A1, ALDH6A1, 
ALDH7A1, ALG10B, ALG13, ALG9, ARG2, 
ATP5G2, ATP6V0E2, BCAT2, COX15, 
COX17, CPS1, CTH, DBT, DHFR, DPM3, 
DTYMK, DUT, ENO1, EPT1, ETNK1, 
FECH, FH, GFPT1, GLCE, GLS, GOT1, 
GPAM, GPAT2, HADH, HADHA, 
HSD17B1, HSD17B2, IDH2, IMPDH2, 
KDSR, LTA4H, MGAT4A, MTHFD1, 
MTHFD2, MTHFD2L, MTR, ODC1, PAICS, 
PFAS, PGM2, PHGDH, PIGK, PIGN, 
PLA2G12A, POLA1, POLD2, POLE3, 
POLE4, POLR2J, PRIM1, PRIM2, 
PTDSS1, PTGES, PTGIS, PYCR2, QARS, 
RRM1, RRM2, SEPHS1, TK1, TKT, 
TUSC3, TYMS, UQCRB, UQCRH, 
UQCRQ, ZNRD1 
8.47E-18 
NOTCH1 
11 CCND1, ENO1, HES6, HEY1, HEY2, 
JAG1, MIB1, MYC, NOTCH1, SKP2, YY1 
2.30E-05 
SOX10 ACC 
signature 
 
26 ABI2, ACTR3B, CADM1, CCNB1IP1, 
CHDH, DPY19L2, EPHA7, FGFR2, 
FRMD4A, GPM6B, ITGA9, LGR6, MTL5, 
MYEF2, NLN, NRCAM, NRTN, PPP1R1B, 
RAP2A, RPL3, SEPT4, SHANK2, 
SLC35F3, TEX261, TMEM63A, TTC3 
1.40E-12 
 
Table 4: Suppressive effects of FABP7 depletion on gene expression in Accx11 cells. 
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II.3.4.7 SOX10, NOTCH1, and FABP7 stimulate spheroidogenesis of Accx11 cells   
NSC and CSC have the propensity to form spheroids in culture.342  Using 
spheroid formation as a surrogate of stem cell survival and proliferation, functional 
consequences of SOX10, NOTCH1, and FABP7 knockdowns were determined.  
Individual depletion of these genes significantly suppressed spheroid formation in 
Accx11 cells (Figure 24C&D).  These data suggest that SOX10, NOTCH1, and FABP7 
are vital for spheroid formation, which could reflect an effect on CSC survival and 
growth.  Flow cytometry analyses of Accx11 were performed to assess the effects of 
SOX10, NOTCH1, and FABP7 depletion on cell cycle progression and cell survival.  A 
marked (~4-6-fold) increase in the subG1 populations, decrease in G1, and increase in 
S phases were observed following NOTCH1, SOX10, or FABP7 depletion (Figure 24E).  
Altogether, these results suggested that NOTCH1, SOX10, and FABP7 are important 
for survival of ACC cells, cell cycle progression, and maintenance of stem-like 
phenotype.  
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Figure 24: Interrelated stimulatory effects of SOX10, NOTCH1, and FABP7 on ACC cells.   
(A) qRT-PCR analysis of SOX10, NOTCH1, and FABP7 expression following siRNA knockdowns reveals their regulatory interdependence.  (B) 
Validation of SOX10, NOTCH1, and FABP7 interdependence by Western blot. β-actin serves as a loading control.  (C) Depletion of SOX10, 
NOTCH1, and FABP7 by siRNA suppresses spheroidogenesis of Accx11 cells at 72 h.  Arrows: brightfield images of spheroids.  (D) Quantification 
of suppressive SOX10, NOTCH1, and FABP7 knockdown effects on spheroids compared to untreated Accx11 cells.  Error bars represent standard 
errors and are representative of at least two independent experiments.  In each case, siRNA knockdown resulted in a significant decrease in 
spheroid formation (p<0.001, Student’s t-test).  (E) Depletion of SOX10, NOTCH1, and FABP7 by siRNA increases sub-G1 cell population 
indicative of cell death.  Histograms represent cell counts based on propidium iodide (PI) staining of Accx11 cells. Percentages of live cells in 
different cell cycle phases are shown. 
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II.3.4.8 NOTCH1 depletion and -secretase inhibition decrease the proportion of 
CD133+, suppress spheroidogenesis, inhibit tumor growth in nude mice, and 
sensitize CD133+ to radiation   
Inhibitors of SOX10 and FABP7 are not available for clinical use at this time, but 
Notch is targeted through -secretase inhibitors (GSI) that have advanced to clinical 
trials.343  The suppressive effects on spheroid formation and cell viability seen with 
NOTCH1 loss (Figure 24C-E) suggested that NOTCH1 is required for survival of 
CD133+ ACC cells.  To test this hypothesis, NOTCH1 was depleted in bulk Accx11 cells 
and the percentage of CD133+ cells was measured.  NOTCH1 depletion resulted in a 
~2.5-fold decrease in the proportion of CD133+ cells (Figure 26A).  Bulk Accx11 cells 
treated with DAPT (a GSI developed by Eli Lilly) showed suppression of spheroid 
formation in a concentration-dependent manner (Figure 26B&C).  To determine if -
secretase activity is also required for maintenance of pre-formed spheroids, Accx11 
cells were grown to confluency to allow spheroid formation as shown in Fig. 1B.  Over a 
9-day time course, a dose-dependent loss of pre-formed spheroids was observed in 
DAPT-treated Accx11 cells compared to controls (Figure 26D); however, the effect of -
secretase inhibition on maintenance of preformed spheroids was not as dramatic as its 
effect on spheroidogenesis and plateaued after six days of treatment.  
Effects of NOTCH1 inhibition on spheroids in Accx11 coupled with analyses 
showing that spheroids are enriched in CD133+ cells suggested that Notch may be 
critical for maintenance and survival of CSC.  To validate DAPT selectivity towards 
CD133+ cells, ACC cells were CD133-sorted and treated with DAPT for 72 hours.  
DAPT treatment suppressed proliferation of CD133+ cells with differences noted at all 
115 
 
doses (1, 5, and 10um), while proliferation of CD133- cells was not affected (Figure 
26E).  FACS analysis confirmed selective DAPT effect demonstrating a ~2.5-fold 
increase in sub-G1 population in CD133+ cells without obvious effects on the G1, S, and 
G2/M ratios.  Neither sub-G1 nor cell cycle progression was altered in CD133- cells 
(Figure 26F).  Annexin and propidium iodide co-staining confirmed that DAPT treatment 
selectively killed CD133+ cells, but did not reveal a pattern typical of apoptosis (Figure 
25).  Finally, to perform pre-clinical assessment of DAPT as a single agent, nude mice 
were subcutaneously injected with Accx11 cells.  In this study, DAPT had a statistically 
significant tumor-suppressive effect starting at week 2 (Figure 26G) but exhibited no 
obvious toxicity.  Overall, these in vitro and in vivo data suggest that GSI effects as a 
monotherapy should be evaluated in clinical trials with ACC patients.  
 
Figure 25: DAPT selectively increases 
cell death in CD133+ Accx11 cells.  
PE-annexin and 7-AAD double staining of 
CD133- and CD133+ Accx11 cells treated 
with DAPT.  DMSO treatment serves as a 
control. 
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Figure 26: Inhibition of Notch signaling selectively depletes CD133+ cells.   
(A) Suppression of NOTCH1 signaling by siRNA decreases the CD133+ cell fraction (red) as demonstrated by FACS analysis using PE-
conjugated CD133 antibody.  (B) Inhibition of Notch signaling with γ-secretase inhibitor DAPT demonstrates dose-dependent suppressive 
effects on spheroid formation (arrows) in Accx11 culture at 48 h.   (C) Quantification of DAPT effects on spheroid formation compared to 
control (DMSO-treated) Accx11 cells, p<0.05 (*), p<0.01 (**), p<0.001 (***), Student’s t-test.  (D) Breakdown of pre-formed spheroids induced 
by DAPT as shown by quantification of remaining spheroids following DAPT treatment versus control (DMSO-treated) Accx11 cells,  p<0.05 
(*), p<0.01 (**).  (E) Inhibitory DAPT effect on cell proliferation is highly CD133+-selective and dose-dependent. At 72 h, there is a statistically 
significant decrease (p<0.01) in luminescence (Cell Titer Glo assay), p<0.01 (**).  (F) DAPT selectively induces cell death in the CD133+ 
population as demonstrated by increase in sub-G1 cell population. Histograms represent cell counts based on PI-staining of separated 
Accx11 cells.  (G) Suppressive effect of DAPT on tumor growth in a nude mouse model subcutaneously injected with Accx11. Starting at 
week2, p<0.01.   
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Because CSC have been implicated in radiation resistance in many tumor 
types,336 the effect of targeting CD133+ cells through Notch inhibition in combination 
with radiation was determined by treating with DAPT for 24 hours and then exposing 
cells to increasing doses of radiation.  Radiation alone had minimal effect on the amount 
of CD133+ cells: even 6 Gy of radiation decreased this fraction only moderately, from 
2.7 to 2.3 %, which translates into a ~15% depletion (Figure 27).  However, DAPT as a 
single agent showed a two-fold (~56%) decrease in the proportion of CD133+ cells.  
Remarkably, when a single 3 Gy or 6 Gy dose of radiation was added to DAPT 
treatment, the combined effect resulted in an almost 2-fold enhancement of CD133+ cell 
depletion as compared with DAPT alone (compare 0.7% with 1.2% in Fig. 5H, p<0.05).  
The enhanced loss of CD133+ ACC cells following radiation in the presence of DAPT 
suggested that combination of radiation with GSI therapy may be worth exploring in this 
radiation-resistant tumor. 
 
Figure 27: Combination of DAPT with 
radiation is more detrimental to 
CD133+ cells (red) than DAPT or 
radiation alone.  
Representatives of 3 replicates are shown 
(p<0.05 in all comparisons except 3 Gy vs 
6 Gy, radiation only).    
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II.3.4.9 NOTCH1 depletion down-regulates SKP2, an E3 ubiquitin ligase that 
targets p27Kip1   
Activated NOTCH1 reduces p27Kip1 levels by stimulating expression of the 
p27Kip1 E3 ubiquitin-ligase SKP2.344  Identification of SKP2 downstream from a 
NOTCH1 effector, FABP7 (Table 4), suggested that SKP2 and p27Kip1 are engaged in 
the pro-survival NOTCH1 signaling in stem-like ACC cells.  Indeed, decreased 
expression of p27Kip1 was noted in CD133+ Accx11 cells, where NOTCH1 was activated 
(Figure 22C&F).  Assessment of SKP2 expression by qRT-PCR and immunoblotting 
showed up-regulation of SKP2 in CD133+ compared to CD133- cells (Figure 28A&B).  
Immunofluorescent staining of Accx11 cultures revealed that SKP2 was detected 
primarily in NR2F1-negative spheroidal cells, and was localized to the cytoplasm, where 
it has been associated with oncogenic activity (Figure 28C).345  Since SKP2 is a 
transcriptional NOTCH1 target, inhibition of NOTCH1 activity is expected to suppress 
SKP2 expression and, in turn, increase p27Kip1 protein stability and levels.  In 
agreement with this expectation, siRNA-mediated NOTCH1 knockdown dramatically 
decreased SKP2 mRNA levels in Accx11 cells, as did DAPT treatment in a dose-
dependent manner (Figure 28D&E).  In order to determine if Notch effects on SKP2 and 
p27Kip1 are seen predominantly in CD133+ cells, bulk Accx11 cells, CD133+, and CD133- 
populations were treated with DAPT for 48 hours, and then cell lysates immunoblotted.  
As expected, CD133+ cells expressed higher levels of N1ICD than bulk or CD133- cells, 
and DAPT effectively inhibited NOTCH1 activation as marked by decreased N1ICD in 
these cells (Figure 28F).  SKP2 was detected at very low levels in bulk and in CD133- 
Accx11 cells (long exposure, data not shown), but was readily detected in CD133+ cells, 
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whereas p27Kip1 was detected in bulk cells and in CD133- cells at much higher levels 
than in CD133+ cells.  Treatment with DAPT did not markedly alter expression of p27Kip1 
in bulk or CD133- cells, but dramatically enhanced its expression in CD133+ cells 
(Figure 28F).  Together, these data suggested that NOTCH1 inhibition up-regulates 
p27Kip1 selectively in CD133+ cells.   
 
 
Figure 28: CD133+-cell-selective and 
NOTCH1-dependent SKP2 expression 
in ACC cells.  
(A-C) SKP2 is selectively expressed in 
CD133+ Accx11 cells as demonstrated by 
(A) qRT-PCR  and (B) immunoblot.  β-actin 
serves as a control.  (C) Spheroid-forming 
CD133+ cells show cytoplasmic localization 
as demonstrated by IF.  (D-E) Inhibition of 
Notch signaling by (D) siRNA and (E) 
DAPT decreases expression of SKP2 in 
bulk Accx11 cells (qRT-PCR).  (F) DAPT 
blocks expression of activated NOTCH1 
(N1ICD) and its target SKP2 in CD133+ 
ACC cells and up-regulates p27Kip1, a 
SKP2 substrate.  β-actin serves as a 
loading control. 
120 
 
II.3.5 Discussion 
  CSCs isolated from various malignancies possess many features of embryonic or 
tissue stem cells and can be targeted via highly conserved Notch, Hedgehog (HH), and 
Wnt pathways activated in these cells.346  While previous studies confirmed the 
existence of CSC in ACC using ALDH as a marker,309 difficulties with ACC culture and 
lack of reliable stem cell markers prevented their characterization.  Our recent studies 
provided a set of novel ACC markers (NOTCH1, SOX10, FABP7) and other genes 
whose expression is associated with propagation and prevention of differentiation of 
NSCs,200, 263 suggesting that isolation of CSC from ACC may be possible.  This study 
developed and implemented a novel technology and an additional set of stem cell 
markers for isolation, propagation, reliable validation, and characterization of these 
cells.  For the first time, ACC cells with CSC properties were isolated directly from tumor 
tissue or propagated and purified from primary ACC cultures.  Using these new 
approaches, a subpopulation of ACC cells expressing SOX10, NOTCH1, and FABP7 
was identified that also expressed CD133, a cell surface marker.  As demonstrated, 
ACC cells that express CD133 have basic characteristics of CSC including the ability to 
generate both CD133+ and CD133- populations, form spheroids in culture, and initiate 
tumors in nude mice.  
Gene knockdown studies highlighted the essential roles and potential functional 
cooperation between NOTCH1 and SOX10 in maintenance of CD133+ ACC cells.  An 
important insight into this cooperation, which has not been previously appreciated, was 
provided by the co-expression of FABP7 that relied on both NOTCH1 and SOX10, and 
the role of FABP7 in regulating expression of genes critical for cell survival.  FABP7 has 
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been recently described as a novel diagnostic and prognostic ACC marker114 and was 
also implicated in glioblastoma, melanoma, and basal-like breast cancer; however, its 
downstream targets and molecular mechanisms of activation have not been studied.  
The current data associate FABP7 with the expression of SKP2 and multiple other 
genes involved in survival, proliferation, and metabolic pathways pointing at a novel 
signaling pathway that stimulates CSC in ACC.  
In this study, SOX10 was one of the most consistent markers of CD133+ stem-
like ACC cells.  Expression of SOX10 is also seen in other cancers with neural crest 
lineage suggesting that they may contain similar stem-like cells.  SOX10 expression has 
been reported in basal-like breast carcinomas, a histologically and clinically distinct 
subtype of breast cancer that lacks targeted therapy and expresses NOTCH1 and 
FABP7.263, 298  It would be interesting to determine if basal-like breast carcinoma is 
SOX10- and NOTCH1-dependent similar to ACC and other neural crest-derived 
cancers such as melanoma, neuroblastoma, and glioblastoma. 
  ACC is a radioresistant tumor, and currently there are no curative treatment 
options for patients with unresectable disease.  Targeting CSC via Notch has been 
linked with sensitization of glioblastoma to radiation.319  Thus, Notch-targeting therapies 
offer a new opportunity for ACC, and while there are no available drugs to inhibit SOX10 
or FABP7, agents targeting Notch are currently in clinical trials.330  This study 
demonstrated that activated NOTCH1 stimulates proliferation and survival of ACC cells 
with neural stem properties.  In line with this scenario, NOTCH1 targeting selectively 
inhibited proliferation of CD133+ ACC cells and triggered cell death resulting in depletion 
of CD133+ cells.  Notch inhibitors have strong antineoplastic activity in numerous 
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preclinical models when combined with DNA damaging therapies,346 and here DAPT 
had single agent efficacy in pre-clinical ACC models and also sensitized CD133+ ACC 
cells to -irradiation.  Overall, these experiments provided preliminary data that stimulate 
interest in Notch inhibitors for ACC therapy either as a single agent or in combination 
with radiation.  
  Mutations in the NOTCH1 gene are detected in 5% of ACCs,78, 79, 347  The low 
incidence of these mutations, however, suggests the existence of other mechanisms 
that trigger Notch activation in ACC.  Intrinsically high NOTCH1 expression in ACC is an 
important pre-requisite for its activation, achieved via ligand-binding.  Hence, 
association of NOTCH1 with JAG1, a NOTCH1 ligand produced by CD133- cells, 
provides a potential mechanism for oncogenic NOTCH1 activation and aggressive 
tumor growth in these tumors.  Indeed, up-regulation of JAG1 has been previously 
linked to NOTCH1 activation and poor survival in breast, pancreatic, and ovarian 
cancers.332 
In search of additional actionable targets associated with NOTCH1 signaling in 
ACC, p27Kip1 and its ubiquitin ligase SKP2 were identified.  SKP2 and p27Kip1 were 
differentially expressed in CD133+ and CD133- cells, with CD133+ cells expressing 
SKP2 and CD133- cells expressing p27Kip1.  Inhibition of NOTCH1 markedly decreased 
SKP2 levels in CD133+ cells and increased protein levels of p27Kip1.  In addition to its 
central roles in the regulation of proliferation, apoptosis, and senescence, which are 
mediated at least partially through degradation of p27Kip1,348 SKP2 is a tumor survival 
factor during energy stress.349  Multifaceted SKP2 activities at a crossroad of many 
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oncogenic signaling axes suggest that SKP2 may be an additional therapeutic target in 
ACC.  
 Overall, characterization of neural stem-like cells in ACC and delineating 
signaling events essential for their maintenance provide a new concept for ACC 
research and treatment that focuses on cancer cells with neural stem properties.  Notch 
inhibitors that show promise in neuroblastoma and brain tumors330 may be used as 
therapy for ACC in combination with Trk inhibition that was previously tested on PDX200 
and cytotoxic modalities.  Future combination strategies for ACC may also include 
SKP2 inhibitors that are currently in development.317 
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III. SUMMARY AND FUTURE DIRECTIONS 
III.1 Summary of studies 
 Some objectives of this work were to: 1) identify molecular markers distinguishing 
ACC from normal salivary gland and other common malignancies of the head and neck; 
2) test the role of identified markers in ACC development and progression; 3) create 
and validate one or more sustainable ACC cell cultures, and; 4) identify potential targets 
for ACC therapy.  Presented here are data which support progress made toward 
accomplishment of these objectives.   
Using microarray datasets from ACC, MEC, HNSCC, AD, and NSG specimens, a 
signature of genes centered around a strong cluster of TrkC probes was identified.  This 
signature suggested characteristics of neural crest stem cells (NCSCs), as well as the 
Notch and Wnt/β-catenin pathways.  While at the time, cell lines were not available for 
ACC, an exogenous expression model of TrkC in U2OS cells devoid of endogenous 
expression of neurotrophin ligands or receptors allowed further investigation of how 
TrkC might be functioning in ACC.  Activation of TrkC signaling by addition of its ligand 
induced TrkC phosphorylation, stimulated proliferation and anti-apoptotic pathways, cell 
motility, migration, invasion, and anchorage independent cell growth.  All NT-3-induced 
effects were reversible by pan-TrkC inhibitor AZD7451.  Additionally, in vitro studies 
using ACC xenografts suggest that TrkC inhibition may be useful for inhibiting tumor 
growth.  While these results suggest a role of TrkC in ACC, further studies are needed 
in ACC cell lines to elucidate the role it is serving within this tumor. 
 Without cell lines available to extend the studies on TrkC, reanalysis of 
expression array data landed focus on SOX10, a gene well described as a marker of 
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NCSCs.  Additionally, SOX10 had been identified as a critical factor for melanoma 
(melanocytes are derived from neural crest) formation and progression.  
Immunostaining of a head and neck TMA confirmed strong staining within ACC 
specimens and clear absence of SOX10 in the vast majority of MEC and HNSCC.  
Analysis of publicly available datasets found strong SOX10 gene signatures within 
tumors of neurologic origin (melanoma, glioblastoma, and neuroblastoma), as well as 
the basal-like subtype of breast cancer.  Comparison of the identified gene signatures 
with the one generated from our own ACC datasets revealed substantial overlap, with 
the greatest similarity existing between ACC and basal-like breast cancer.  Interestingly, 
these tumors are both believed to arise from myoepithelial cell-containing areas of 
structurally similar glands.  In addition to being a sensitive biomarker of these tumors, 
basal-like breast cancer cell lines harboring SOX10 expression maintained 
characteristics of both positively- and negatively-associating SOX10 signature genes in 
culture, suggesting that this network may be important for maintenance of these cells.   
 In order to further analyze the role of SOX10 in ACC, tumor cells from ACC 
xenografts were successfully cultured by utilizing a new technique for cell culture.  A 
robust culture, Accx11, continued to grow in culture beyond 30 passages and 
maintained expression of ACC markers including SOX10.  In culture, Accx11 cells 
displayed characteristics of stem-like cells including spheroidogenesis.  Cell sorting 
based on expression of CD133 of Accx11 cells and dissociated xenografts generated a 
CD133+ cell population enriched with markers of ACC including SOX10, NOTCH1, and 
FABP7, as well as downstream targets of Notch signaling.  Conversely, CD133- cells 
expressed markers of neural differentiation and the Notch ligand JAG1, suggesting that 
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CD133- cells may differentiate from CD133+ cells and function to support the CD133+ 
cell population.  Mouse injections of sorted cells confirmed CD133+ cells as being more 
tumorigenic than their CD133- counterparts.  Knockdown experiments using siRNA 
demonstrated interrelated signaling between SOX10, NOTCH1, and FABP7, and that 
CD133+ cells were dependent upon each of these proteins.  Although pharmacological 
agents are not available for inhibition of SOX10 and FABP7, Notch pathway inhibition 
using the γ-secretase inhibitor, DAPT, reduced the CD133+ cell population, suppressed 
spheroidogenesis, and sensitized CD133+ cells to radiation.  These data open up new 
avenues to be explored in the treatment of ACC. 
III.2 Future directions  
 The findings in these studies have provided new insights into the molecular 
landscapes and signaling networks involved in ACC.  In particular, generation of the 
short- and long-term ACC cultures creates an experimental platform for testing new 
ideas.  In addition, isolation and characterization of CSC in ACC creates a new concept 
of CSC targeting in this tumor type. 
III.2.1 SOX10 in breast cancer 
While ACC remains an insidious tumor with poor patient outcomes, it is an 
orphan tumor affecting approximately 1200 people annually in the United States.  Some 
of the most exciting findings presented here are the conserved expression patterns 
seen in distinct tumor types that share their neural crest origin.  A conserved signaling 
pathway in neural crest-associated tumors suggests that targeting this pathway may 
have far-reaching effects on a myriad of tumors.  Amongst tumors examined, basal-like 
breast cancer demonstrated the highest similarity to the SOX10 co-expression gene 
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profile found in ACC.  Basal-like breast cancer is a common malignancy with severely 
limited treatment options.  Importantly, SOX10 is critical for melanoma tumorigenesis, 
maintenance, and progression, and data presented here suggests that SOX10 plays a 
critical role in the maintenance of stem-like cells within ACC. 
The most strongly negatively correlating gene to SOX10 in both ACC and basal-
like breast cancer is FOXA1.  While the implications of FOXA1 expression in ACC 
remain unknown, in breast cancer, it can have profound implications.  In luminal breast 
cancers, FOXA1 is required for ~50% of the function of ESR1, suggesting that the lack 
of FOXA1 in basal-like tumors may, in part, contribute to the lack of ESR1 expression in 
these tumors.  Moving forward, studies inhibiting SOX10 expression in basal-like breast 
cancer cell lines MX-1 and HCC1569 will help to identify how SOX10 is contributing to 
the behavior of these tumors.  Potentially, even if SOX10 inhibition alone is incapable of 
killing tumor cells, this may reverse FOXA1 suppression allowing for ESR1 function.  
While SOX10 is not currently targetable by clinically available therapeutics, SOX10 
targeting could allow for new avenues for pharmaceutical intervention. 
III.2.2 Generation of ACC cultures from primary tumors 
The history of cell culture in ACC is a sordid affair.  From contamination to 
unexplained losses of DNA mutations central to the parent tumor, ACC cultures have 
been notoriously unreliable.  Now that a reliable culture system for ACC cells 
dissociated from tissues has been optimized, it should be utilized to create additional 
cultures.  In addition to providing tools for ACC research, additional cultures will allow 
for validation of findings and avoid limitations and biases that limited numbers of 
specimens or cultures can produce.  While Accx11 displays markers characteristic of 
128 
 
ACC, it is derived from xenografted tissue, which will have changed due to the selection 
induced by growing in mice.  As experience culturing with the CRC system has 
increased, the ability to successfully generate cultures from small tissue specimens has 
improved.  This is important as, moving forward, the goal is to produce cultures from 
primary ACC tumors without the need for xenograft expansion.   
III.2.3 TrkC function in ACC cell culture 
 Accx11 maintains a large variety of ACC markers, which can be manipulated for 
in vitro and in vivo studies.  In particular, TrkC results, generated primarily in U2OS 
cells, will be reassessed.  Currently planned are proliferation, migration, invasion, and 
expression studies on Accx11 cells with or without stimulation of TrkC with its ligand, 
NT-3.  Additionally, having already identified CD133+ stem-like cells in this culture, 
future studies will focus on assessing TrkC expression in these cell subpopulations.  
Should TrkC expression be associated with any of the phenotypes seen previously in 
U2OS cells in vitro, injections of Accx11 cells for mouse xenograft experiments using 
AZD7451 or other Trk-family inhibitors will be performed to see how pharmacological 
intervention may affect these phenotypes in vivo.   
III.2.4 MYB-NFIB and MYBL1-NFIB gene fusions in ACC 
 Until now, studies have only been able to confirm the existence of the MYB-NFIB 
and MYBL1-NFIB gene fusions or analyze the expression of MYB in ACC tumors.  The 
ability to culture ACC cell from xenografts and primary tumors provides a unique 
opportunity for studying these fusions and their roles in ACC.  Break-apart FISH studies 
demonstrated MYB-NFIB gene fusions in seven of the nine PDX models described and 
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used in our lab, including ACCX11.  Preliminary studies on current ACC cultures 
suggest the presence of at least two distinct MYB-NFIB fusions which have been 
previously described.  Using si/shRNA and CRISPR targeting sequences within the 
MYB open reading frame, MYB expression will be suppressed in culture in order to 
determine expression and cell behavior changes in vitro.  Further studies are planned to 
determine the role MYB serves in tumorigenicity in vivo and to determine if MYB 
expression is limited to CSCs or alters CSC behavior.  Particular interest will be focused 
on inducible loss of MYB in order to determine if established tumors maintain 
dependence on MYB.  
III.2.5 NOTCH inhibitors in development 
 The presented studies demonstrate that inhibition of NOTCH selectively kills 
ACC cells with stem-like properties in vitro resulting in reduced tumorigenicity.  
However, clinically, GSIs have primarily performed poorly as a single agent, largely due 
to gastrointestinal side effects induced by even low doses.  Fortunately, efforts are 
being made to create small molecules and antibodies to inhibit NOTCH that do not 
function through γ-secretase.  These inhibitors intend to specifically target NOTCH 
isoforms, which in turn will reduce side effects in noncancerous cells.  As these drugs 
become available, their efficacy will be tested on ACC cultures. 
III.2.6 Combinatorial treatment of ACC 
 As with most tumors, it is unlikely that a single agent will be successful in treating 
ACC, due to the development of resistance.  Identification of additional pathways 
employed in ACC for tumorigenic purposes will hopefully allow a combination of 
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therapies for control, palliation, or cure of this disease.  These studies have 
demonstrated that TrkC, SOX10, and NOTCH1 all play important roles in the 
development and maintenance of ACC.  Moving forward, effects of combinatorial 
inhibition of NOTCH1 and TrkC on tumorigenesis of injected cells and xenografts will be 
studied.  Additionally, the presented in vitro studies suggest that NOTCH inhibition with 
GSI can sensitize ACC cells with stem-like properties to radiation, something important 
to confirm in vivo.  Other potential pathways for therapy include MYB (as discussed 
above) and WNT signaling, both of which are topics for further study using the tools and 
cultures that we have created. 
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